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Up to now, cancer represents one of the most challenging disease to treat, mostly 
due to its ability to adapt and negatively respond to current available therapies. Over 
the past 30 years, Ribosome Inactivating Proteins (RIPs) have attracted great 
interest in the scientific community for their therapeutic potential. Indeed, such 
toxins have been extensively used as potent and versatile therapeutic weapons due 
to important advantages compared to chemotherapeutics: for instance, they act 
independently form cell cycle, killing both quiescent and dividing cells, limiting 
the development of cancer resistance. However, the successful application of 
toxins-based therapeutics to solid tumors remains to be demonstrated. In this study, 
we explored the potential use of the plant-RIP saporin (SAP) for the treatment of 
solid tumors. In particular, we propose two different strategies, in which SAP is 
selectively and safely conveyed to malignant cells either in the form of recombinant 
protein through genetically fused targeting moieties, or throughout cell-derived 
extracellular vesicles as vehicles. Previous studies have shown that the urokinase 
receptor (uPAR)- targeting ATF-SAP chimera improved the therapeutic index of 
the toxin in vitro on uPAR expressing cells. To explore SAP therapeutic 
applicability, in this study we compare and combine ATF-SAP toxic activity to a 
new an-integrins-targeting recombinant protein (RGD-SAP) with the aim to cope 
with tumor heterogeneity, targeting both tumor epithelial and endothelial cells. The 
recombinant proteins resulted in a safe and cancer specific toxicity in plenty tumor 
cell models, which was proportional to the receptors expression levels on cells 
surface. Receptor recognition by targeting moieties was not impaired by the 
presence of the toxin, as, in case of RGD-SAP, competitive binding experiments 
induced a partial rescue of cell viability. In addition, in vivo results showed that 
recombinant proteins are able to induce potent antitumor effects in bladder tumor-
bearing mice, either when used as single treatment or in combination. Eventually, 
we demonstrate that SAP delivery can be improved by the use of extracellular 
vesicles (exosomes) as drug nanocarriers. Specifically, we propose a “genetic” 
method, in which we genetically engineered cells to produce targeted therapeutic 
exosomes, using Lamp2b as exosomal resident protein, or a “chemical” method, 
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based on a pH shock exposition, to achieve SAP incorporation. We show that, in 
contrast to previous studies, the expression of Lamp2b fusion proteins is not a 
suitable method to achieve a sustained production of engineered exosomes, in 
contrast to tetraspanins, that are massively incorporated into the vesicles. In 
addition, we demonstrate that a protease-dependent smart prodrug system is 
promising for the selective release of the cargo in target cancer cells. On the other 
hand, a highly alkaline solvent is able to induce a massive SAP encapsulation in 
exosomes compared to commonly used techniques, preserving exosomal size, 
structure and integrity and mediating a higher toxicity compared to SAP alone. 
Overall our data indicate that SAP-based recombinant proteins are promising anti-
tumoral therapeutic options. Applied as single or combined treatment, as well as 
used together with traditional therapeutics, they appropriately address both intra- 
and inter- tumor heterogeneity. In addition, the use of exosomes as SAP 





1.   Introduction 
  
1.1  State of the art therapies against cancer and their limitations 
 
Cancer is one the major causes of death worldwide. Current clinical protocols are 
mostly based on the combination of surgical resection to debulk, followed by 
radiation and chemotherapy. However, not all tumors can be completely eradicated 
by surgery as they might have spread to nearby organ/tissues or metastasized 
throughout the body. The drugs used in the classical chemotherapy, approved for 
the treatment of a variety of tumor types include predominantly small molecules 
like cisplatin, taxol, doxorubicin and anthracyclines, which target the rapidly 
growing cells, blocking cell proliferation and DNA replication. Albeit in some 
cases efficient in reducing or completely eradicating tumor mass, these kinds of 
therapies suffer from two big limitations: lack of a specificity and poor solubility 
in water. They kill cells in a cell cycle dependent manner, causing an increased 
toxicity against normal tissues, like bone marrow, intestinal epithelial cells and hair 
follicles besides rapidly dividing cancer cells. Moreover, most of the 
chemotherapeutics are chemically synthetized, highly hydrophobic compounds and 
minimally hydro-soluble, requiring oily moistures or lipophilic solutions to 
solubilize the formulation, thus contributing to their toxic effect on patients’ body. 
Therefore, the ability of the patients to tolerate and afford the side effects have to 
be considered when the appropriate treatment is decided. 
Targeted therapies have gained great attention in the last decades as they opened up 
the possibility to specifically deliver drugs to diseased tissues and kill cancer cells 
without or minimally affecting healthy organs. The target specificity is addressed 
by the interaction of drugs with molecules, mainly proteins, exclusively expressed 
or overexpressed in cancer cells. In fact, progression and dissemination of 
malignant cells is characterized by the acquisition of novel functional competences, 
including self-sufficiency in growth signals, insensitivity to anti-growth signals, 
evasion of apoptosis, limitless replicative potential, sustained angiogenesis and 
tissue invasion. Several of those novel functions are linked to the massive-
expression of surface receptors, usually growth factors, whose identification could 
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lead to the development of effective and personalized treatments. Recently, the 
molecular diagnostics is rapidly developing, and more and more targeted 
therapeutic agents have been approved by the US Food and Drug Administration 
(FDA) across many cancer subtypes, providing new treatment options to patients 
who cannot receive chemotherapy. These therapies include hormone therapies, 
signal transduction inhibitors, gene expression modulators, apoptosis inducers, 
angiogenesis inhibitors, immunotherapies and toxin-based drugs 
(www.cancer.gov). Even if safer, these approaches are not free from drawbacks. In 
fact, patients can stop responding to the treatment throughout complicate, tumor 
specific mechanisms that result in alterations of the drug target, activation of pro-
survival pathways and ineffective induction of cell death, that can be collectively 
defined as multidrug resistance [1]. Furthermore, the high intra- (within a tumor) 
and inter- (tumor by tumor) tumor heterogeneity remarkably limit their use to be 
applied to different cancer subtypes. Other problems that hinder the widespread use 
of targeted therapies are related to their size and, thus, poor penetration into the 
tumor mass. Monoclonal antibodies, for instance, nowadays represent one of the 
most successful strategies adopted for both hematological and solid tumors but have 
a high molecular mass (around 150 kDa), generally causing an inadequate 
pharmacokinetics and tissue accessibility. Even if fragmented derivatives have been 
developed (using just the small chain variable fragment -ScFv-), high dosage 
administrations are still required to achieve clinical efficacy, due to the limited 
duration of action, contributing to undesired immunogenicity and toxicity [2].  
 
1.2  Tumor microenvironment and its associated therapeutic targets 
 
As a pathologic condition, solid tumors microenvironment is extremely abnormal: 
blood flow is low with low perfusion, due to a vascular hyper-permeability and the 
lack of functional lymphatic vessels results in an elevated interstitial fluid pressure 
(IFP). A large number of active stromal cells and extracellular matrix (ECM) are 
often dense and stiff, compressing the blood vessels, which represent one to 10% 
of the volume of the tumor mass. The remaining space is filled primarily by an 
abundant collagen-rich matrix, the interstitium. [3, 4]. Due to this complex and 
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hostile architecture, systemically administered small-sized anticancer drugs 
preferentially leak and passively accumulate in the tumor tissue (enhanced 
permeability and retention -EPR- effect). However, even if widely exploited to 
improve treatment efficacy, this “passive targeting” process is not sufficient to 
guarantee the delivery of appropriate concentrations of drugs to tumor environment 
just by itself. Anticancer drugs, in fact, need to undergo and accomplish a three-
step process to exert their therapeutic effect, including: 1- vascular transportation 
to different areas of the tumor; 2- trans-vascular transport across the vessel wall: 3- 
interstitial transport to reach the tumor cells [5]. Therefore, drugs able to either 
passively accumulate into the tumor throughout the EPR effect and actively target 
malignant cells would be a smart strategy to improve the therapeutic index. 
Endothelial cells are the first cell type directly exposed to the circulating drugs and, 
thus, more accessible to them. The elimination of a single endothelial cell leads to 
the indirect killing of tumor cells due to the lack of oxygen and nutrients [6]. In this 
contest, an- integrins represent one of most suitable class of molecules to be 
targeted, owing to their augmented expression in several human malignancies. In 
cancer, their presence on both endothelial and epithelial cancer cells compared to 
normal cells regulate many steps of tumor progression, including angiogenesis, 
spreading, migration, growth signaling, survival signaling, secretion of proteases 
and invasion [7, 8, 9]. They are heterodimeric membrane glycoproteins composed 
by non-covalently associated α- and β-subunits that act as adhesion receptors for 
extracellular matrix (ECM) proteins, immunoglobulin, growth factors, cytokines, 
and matrix-degrading proteases, by binding their ligands often through recognition 
of short amino-acid sequences. A subset of integrins, for instance, recognize the 
arginine-glycine-aspartic acid (RGD) motif within their ligands (i.e. fibronectin, 
vitronectin, laminin). This binding results in the transduction of the information 
from the extracellular environment to modulate cell response [10, 11].  Among 
integrins, anb3 is probably the most strongly involved in the regulation of 
angiogenesis. It localizes with proteolytically active metalloprotease (MMP)-2 on 
the surface of angiogenic blood vessels, playing an important role in cell-mediated 
collagen degradation and consequently rearrangement of the ECM [12]. About 480 
drugs targeting integrins have been developed and tested so far in clinical trials with 
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multiple indications, but unfortunately, only few inhibitory antibodies (abciximab; 
tirofiban; eptifibatibe; natalizumab; vedolizumab; and lifitegrast; with efalizumab) 
reached the clinical market, because of integrins complexity and different 
regulation in human cancers with respect to preclinical mouse model [13].  
Besides integrins, the urokinase plasminogen activator receptor (uPAR) represent 
a good candidate as a target for innovative cancer therapies. It is a glycoprotein of 
55-60 kDa, associated to the external surface of the plasma membrane by a 
glycosyl-phosphatidylinositol (GPI) anchor and an important regulator of the 
plasminogen activation system (PAS), an extracellular proteolytic cascade 
responsible for the extracellular matrix (ECM) degradation. Upon binding its 
natural ligand, the urokinase plasminogen activator (uPA), uPAR allows the 
conversion of plasminogen into the serin-protease plasmin, which reciprocally 
cleaves and activates pro-uPA and matrix MMPs, thereby facilitating cell migration 
by tissue remodeling. Thus, uPAR plays a pivotal role in microenvironment 
modification, promoting ECM proteolysis and ECM interaction. It participates in a 
number of transitory physiological processes that require blood vessels formation 
and degradation of the ECM (menstrual cycle and trophoblast implantation, 
embryonic development, inflammation and wound healing), being expressed by 
cells that are in motion, such as activated leukocytes, endothelial cells and 
fibroblasts [14]. However, uPAR expression is significantly upregulated in cancer 
under particular stimuli (such as hypoxia), where the reorganization of tumor 
microenvironment leads to cancer cells to migration, angiogenesis, vascular 
invasion and propagation to distant sites. Furthermore, uPAR activation is also 
involved in intracellular signaling pathways of migrating cells, mainly through 
interactions with co-localized integrins (b1, b2, and b3 integrin receptor families) 
[15] and tyrosine kinase receptors (EGFR), that result in the activation of cell 
survival and proliferation pathways [16]. In agreement with its roles in cancer 
progression, the importance of uPAR is widely strengthened by a positive 
correlation between its levels and patient outcome/low overall survival in most 
human solid and hematological malignancies, among which breast [17] and bladder 
cancers [18]. The only therapeutic monoclonal antibodies that specifically target 
uPAR developed so far are HuATN-658 (Cancer Research UK’s Centre for Drug 
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Development) and ATN-658, shown reliable preclinical anti-tumors effects across 
a variety of tumor models, blocking the interaction between uPA and uPAR [19] 
and, thus, inhibiting invasion, metastasis and tumor proliferation as well as inducing 
apoptosis. 
 
1.3  αv-integrins and uPAR targeting peptides 
 
In the last years, many investigators have explored the potential of targeting 
peptides, a promising class of molecules that, owing to their small size, low 
immunogenicity, ease of manufacture at reasonable costs, can overcome many 
monoclonal antibodies-associated limitations. They are usually obtained from the 
binding region of the main ligand of the protein of interest or selected from 
combinatorial phage display libraries (∼1011 different sequences) to identify the 
sequences with the higher affinity that may improve tumor homing property. For 
instance, most integrins recognize their respective ECM proteins through short 
peptide sequences such as Arg- Gly-Asp (RGD), Glu-Ile-Leu-Asp-Val (EILDV), 
or Arg-Glu-Asp-Val (REDV). Therefore, these sequences have been exploited to 
synthetize integrins-specific peptides and shown to be endowed with a high 
therapeutic activity. One of the first RGD-based integrins targeting peptide 
developed was Cilengitide (EMD121974), from Merck KGaA, a cyclic 
pentapeptide that specifically inhibits αvβ3 and αvβ5 [20]. Preclinical studies have 
demonstrated its efficacy as anti-angiogenic and anti-tumor agent, suppressing 
breast metastasis to bone and favoring radiotherapy efficacy in orthotopic brain 
tumors models [21, 22]. However, it has been observed that if, on one hand, this 
cyclic peptide is able to enhance intra-tumoral vascular permeability and increase 
drug delivery [23], on the other, nanomolar concentrations of cilengitide activate 
αvβ3 and enhance angiogenesis and tumor growth [24]. Furthermore, as for many 
inhibitory targeting peptides, unsuccessful early trials revealed its rapid clearance 
from serum (t1/2 = 3–5 h) [25]. Therefore, other strategies have been adopted in 
order to exploit RGD-based targeting peptides to achieve drug delivery to tumors 
other than as therapeutics themselves. ACDCRGDCFC peptide, in particular, has 
been proven to enhance the selective delivery of antitumor compounds to tumor 
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vessels, binding to integrins, such as αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, with 
different affinity and selectivity and allowing the “active targeting” of both 
endothelial and epithelial tumor cells [12, 26, 27, 28]. Importantly, RGD-targeted 
compounds have been demonstrated to be internalized via receptor-mediated 
endocytosis, particularly interesting aspect for the intracellular delivery of drugs to 
cancer cells [12]. As for integrins, uPAR targeting peptides have also been 
developed to overcome antibodies limitations. In this case, they were not used as 
such to inhibit uPAR signaling activity, but mostly in conjugation to cytotoxic 
moieties or nanoparticles to address uPAR expressing cancer cells in in vitro 
studies. The first peptide was created by isolating the amino-terminal fragment 
(ATF) of uPAR natural ligand, uPA, containing the initial 135 amino acids 
including the growth factor domain [29, 30]. The ATF peptide was shown to be 
highly efficient in the in vitro specific delivery of a biological toxic compound to 
uPAR overexpressing hematological tumors (30, 31). Since then, two more uPAR 
targeting peptides have been derived from the uPAR binding sequence of ATF, 
consisting of 7 or 11 amino acids, named U7 and U11. They were proven to be 
uPAR-specific in cellular model of breast and prostate cancer [29, 32, 33]  
 
1.4  Urothelial bladder cancer 
 
Urothelial bladder cancer (UBC) is one of the leading causes of death in developed 
counties, three to four times more prevalent in males than in females. The prognosis 
and treatment of bladder cancer have improved little in the past 20 years and it 
remains among the most expensive cancer to treat (life-long clinical management 
of patients with non-muscle invasive disease as well as costs associated with caring 
for patients after radical cystectomy, surgical removal of the bladder). A staging 
system (TNM system), ranging from stage 0 (carcinoma in situ) to stage 4 (the most 
advanced one) is a standard way to describe the extent of cancer spread and it is 
based on three specific parameters: T describes how far the main (primary) tumor 
has grown through the bladder wall and whether it has grown into nearby tissues; 
N indicates if cancer cells have spread to lymph nodes near the bladder; M describes 
if the cancer has metastasized to distant organs or lymph nodes. Although 
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characterized by heterogeneous further subtypes that have a range of disease 
outcomes, the broad subgroup (70-75%) is represented by non-muscle invasive 
bladder cancer (T0 and T1), which is more common and usually associated with a 
favorable prognosis. The remaining 25-30% of bladder cancer is muscle invasive 
(T2, T3 and T4), less prevalent, but typically associated with poor prognosis. The 
optimal treatment for UBC depends on the cancer's stage, reflecting the depth of 
invasion of the primary tumor through the bladder wall and nearby tissues 
[http://www.cancer.net/cancer-types/bladder-cancer/stages-and-grades/trackback]. 
The prognosis of the tumor in the initial phase is generally favorable and finds an 
easy resolution through the endoscopic removal of the lesion. However, more than 
50% of patients undergoing primary tumor resection face further problems due to 
cancer relapse [34]. In patients with superficial or non-muscle invasive tumors, pre- 
(neoadjuvant chemo) or post-surgical (adjuvant chemo) endovesical chemotherapy 
is a first line of intervention aimed at reducing the number of relapses but has 
limited efficacy and non-negligible side effects at the local level [35]. The second 
line of intervention is instead constituted by the immunotherapy which involves the 
endo-vesical use of Bacillus Calmette-Guerin (BCG) or the chemotherapeutic 
mitomycin. In the case of infiltration of the bladder wall by the tumor (which is 
therefore defined as muscle invasive), cystectomy represents the standard 
intervention. Following cystectomy, 5-year survival is below 50%, depending on 
the degree of infiltration of the bladder wall, the presence of extra-vesical extension 
and the presence or absence of metastases in the lymph nodes [36]. However, 
cystectomy is not a valid treatment for patients presenting metastases. In this case, 
the preferential intervention line is represented by a systemic chemotherapy 
regimen consisting of methotrexate, vinblastine, adriamycin and cisplatin (MVAC) 
or, alternatively, gemcitabine associated with cisplatin (GC), both with a low 
response rate (~ 40-50%) and a limited increase in survival (12-15 months) [37]. 
Although these drugs have a broad spectrum of activity and are partially effective 
in the treatment of bladder cancer, severe side effects limit their use. In fact, they 
totally lack specificity and need to be administered in very high doses to reach the 
active concentration at the tumor sites. Patients who cannot tolerate chemotherapy 
(because of other health problems) are treated with radiation therapy or with 
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immunotherapy, such as atezolizumab (anti PD-L1) or pembrolizumab (anti PD1) 
[www.fda.gov]) [38]. In this context, many efforts are focused on the development 
of a targeted therapy, aimed at inhibiting or exploiting specific tumor pathways and 
receptors to selectively kill the neoplastic cells [39].  
 
1.5  Breast cancer  
 
Breast cancer is a highly genetically and clinically heterogeneous disease that 
represents the second leading cause of death among women in the world. Every 
year, in fact, the number of diagnosed breast cancer cases have been estimated to 
be 1 to 1.3 million. Of these, approximately 15- 20% belong to the triple-negative 
subtype (TNBC). TNBC is the most biologically aggressive breast cancer subtype, 
with an increased likelihood of distant recurrence and of death compared to the 
others. Its phenotype is defined by the lack of expression of estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), 
therefore hormone therapies and anti-HER2 targeted therapies are not effective 
[40]. Due to the current absence of a recognized therapeutic target and the high inter 
and intra-tumoral heterogeneity, the primary line of intervention is represented by 
a combination of surgery, chemotherapy (with international guidelines supporting 
the use of single-agent taxanes or anthracyclines [41]) and radiation therapy. In 
some cases, a neoadjuvant chemotherapy is given to shrink tumor before surgery. 
Despite initial good response, only 20% of patients respond well to standard 
chemotherapy and their prognosis remains poor as compared to non-TNBCs [42]. 
At present, PARP inhibitor Olaparib is the only molecular-based targeted therapy 
for BRCA1-mutation presenting patients with TNBC, but only approximately 10-
20% of them positively respond to the treatment [43, 44]. Thus, developing 
improved treatments for TNBC is one of the highest priorities of current breast 
cancer research.  
 
As no effective specific targeted therapies for both bladder and triple negative 
breast cancers are readily available, the exploration of novel therapeutic markers 
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and the development of new agents with therapeutic potential need in-depth 
investigations.   
 
1.6  Toxins therapeutic potential 
 
Toxins are natural dangerous molecules produced by bacterial or plant that have 
been structurally and functionally optimized under evolutionary pressure as 
defensive strategy against predators. Many research groups turned to explore their 
pharmaceutical potential when used to efficiently impair essential cellular 
processes and induce cell death. Indeed, acting in a cell cycle independent manner, 
they can kill both quiescent and rapidly dividing cells, resulting suitable to fight 
both tumors with a slower progression and aggressive cancers. Toxins use as 
effectors in cancer therapy has been studied for decades with promising results. 
Pseudomonas exotoxin A (PEA) and diphtheria toxin (DT) from bacterial origin, 
for instance, have been employed for diverse therapeutic purposes [45] mainly in 
the form of immuno-conjugates. The presence of an antibody portion or ligand 
domain confer target specificity, providing an antigen-specific binding affinity to 
molecules over-expressed on the surface of malignant cells. The most successful 
developed toxin-based drug is Denileukin diftitox, the first recombinant protein 
formed by a truncated form of DT and human cytokine interleukin-2, approved by 
the US Federal Drug Administration (FDA), for the treatment of cutaneous T-cell 
lymphomas. Numerous other toxin-based conjugates are under investigations in 
pre-clinical and clinical trials against hematological as well as solid tumors with 
encouraging results [46]. However, as mentioned before, the major obstacles to 
successful treatment of solid tumors using immunotoxins (Its) include multiple 
factors, among which the poor penetration into tumor masses. Solid tumor core is 
not easily accessible, and the drug effect is often confined to the surface of the 
tumor mass. Moreover, the other limiting factors are represented by the dimensions 
of the antibody portion and the activation of the immune response against the 
antibody component, which limits the number of treatment cycles. Furthermore, 
even if the dimension problem has been overcome by using only the small variable 
fragment of the antibody, the cost and scaling of production of these compounds 
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remain constraining. Another promising way to exploit toxins as a pharmacological 
weapon is to design recombinant chimeras/recombinant proteins consisting of a 
fusion between the catalytic domain of the toxin and a tumor targeting ligand 
domain, usually a growth factor [47]. The advantages of these compounds are 
related to the reduced dimensions (the targeting moiety is generally a small peptide 
composed by a small number of amino acids), which ameliorate the penetration 
capacity into the tumor environment (EPR effect), and immunogenicity, thus 
prolonging the half-life of the therapeutic protein. In 2002 Vallera et al. [48] 
produced a recombinant protein fusing diphtheria toxin (DTAT) to the amino 
terminal fragment (ATF) of uPA, demonstrating its in vitro biological activity on 
human uPAR positive glioblastoma cells (U118MG) (IC50 <1 nM). They also 
showed that DTAT was able to regress U118MG tumours in mice. A recombinant 
protein consisting in ATF fused to a truncated form of Pseudomonas exotoxin has 
similarly been prepared and shown to be highly active on breast cancer cell line 
MCF7(IC50 = 2.8 pM) [49].  
Plant derived Ribosome-Inactivating Proteins (RIPs), are suitable candidates to 
pursue this latter strategy. They belong to the N-glycosidase family of toxins able 
to depurinate a specific adenine base located in the universally conserved GAGA 
tetraloop in the 23/26/28S rRNA. This activity results in the inability of the 
ribosome to bind the elongation factor 2 and, thus, in the irreversible inactivation 
of protein translation, causing apoptotic cell death [46, 50]. Plant RIPs have been 
classified into three main groups: type I RIPs are composed of a single polypeptide 
chain with catalytic activity; type II RIPs are heterodimer consisting of an A chain, 
functionally equivalent to the type I polypeptide, linked to a B subunit, which is 
endowed with lectin-binding properties; type III RIPs are polypeptides synthesized 
as inactive precursors (ProRIPs) that require proteolytic processing to form an 
active RIP [50]. The lack of a specific binding domain in types I RIPs natural 
structure have allowed their direct exploitation as catalytic moiety of recombinant 
chimeras. In this class of molecules, saporin (SAP) is one of the most studied 
because of its strong intrinsic activity both in cell-free systems and in cell lines and 
its unusual resistance to high temperature, denaturation and attacks by proteolytic 
enzymes, making it a suitable candidate for therapeutic intervention. Its 
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internalization pathway has been demonstrated to involve the low-density 
lipoprotein receptor (LDLR) family that includes seven closely related family 
members: the very-low-density lipoprotein (VLDL) receptor, apoE receptor 2, 
multiple epidermal growth factor-like domains 7 (MEGF7), glycoprotein 330 
(gp330/megalin/LRP2), lipoprotein receptor-related protein 1 (LRP1), and LRP1B 
[50]. Among these, the α2-macroglobulin receptor/low-density lipoprotein 
receptor-related protein 1 (LRP1) in particular was shown to bind saporin in vitro 
[51, 31], mediating saporin internalization in human monocytes and fibroblasts [52, 
53]. Furthermore, downregulation of LRP in human U937 lymphoma cells as well 
as its knock out in mouse embryonic fibroblasts (MEF) resulted in an increased 
resistance to saporin [52, 54]. Saporin-based uPAR targeting conjugate, carrying 
the entire pro-uPA sequence [55] and a saporin-based recombinant chimera, in 
which saporin was fused to the amino terminal fragment (ATF) of uPA [29, 31, 32] 
were found to specifically recognize and bind uPAR overexpressing cells in in vitro 
studies, therefore modifying the internalization pathway of the toxin and making it 
dependent on the expression of the target molecule, paving the way for the use of 
targeting toxins as anti-cancer therapeutic strategies. 
 
1.7  Nanotechnology to improve drug delivery 
 
In recent years, outstanding progresses have been achieved by using 
nanotechnology to increase the targeted delivery of drugs. Among them, drugs-
encapsulating nano-vectors, such as liposomes, currently represent a preferred 
system, offering several advantages compared to the use of drugs themselves. In 
fact, they enable a reduced systemic toxicity, enhanced drug solubility and 
improved homing in diseased tissues, as the drug is “protected” inside the carrier, 
it is not subjected to degradation by serum components and could be better retained 
in the tumor mass through both an active (surface customization) or passive 
targeting (EPR effect) mechanism. However, the ability of an ideal liposome to 
evade the host immune system and achieve a longer circulating capability and 
stability still remains elusive [56]. In this contest, naturally secreted nano-sized 
extracellular vesicles (exosomes) appear to be a preferable choice, offering 
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important advantages compared to synthetic liposomes, among which: 1) lack of 
immunogenicity and cytotoxicity, due to their composition, which resembles 
body’s own cells; 2) improved circulation time, decelerating mononuclear 
phagocyte system-mediated clearance; 3) innate stability in biological fluids. These 
features, together with the average nano-scaled size (50-200 nm) that allows them 
to easily penetrate in almost all body districts and cross biological barriers, the 
cargo protection and the customizable surface, make them ideal nanocarriers for 
targeted drug delivery [57].  
 
1.7.1   Exosomes biogenesis, isolation and characterization 
 
Exosomes are small extracellular vesicles that originate from the inward budding 
of the membrane of late endosomes that results in the formation of vesicles inside 
the lumen. The neo-formed structure, called multi-vesicular body (MVB), can 
either fuse with lysosome for degradation or with the plasma membrane of the cell, 
releasing its exosomes content in the extracellular environment. Therefore, 
exosomes molecular composition is associated with MVB biogenesis and includes 
nucleic acids, transport proteins, heat shock proteins, soluble proteins and 
membrane proteins such as tetraspanins. In addition to proteins, exosomes are 
characterized by different types of lipids, such as cholesterol, sphingolipids, 
phosphoglycerides, ceramides and saturated fatty acid chains [58], present in highly 
abundant amount. This peculiar lipid composition allows the use of fluorescent 
lipophilic dyes to stain their membrane and trace their intracellular fate. 
Importantly, exosomes molecular composition is critical, since they provide an 
indication of their functions in biological processes. Therefore, it is very important 
to select the proper cell type as origin of exosomes to be used for a therapeutic 
purpose. Different exosomes isolation methods have been optimized over the years 
[59]. The most common one consists in differential centrifugation steps, whereby 
cell debris and large particles (microvesicles and apoptotic bodies) in the culture 
medium are eliminated using low centrifugal force and exosomes are collected 
from supernatant by high speed ultracentrifugation. Other isolation techniques 
include the use of flotation density gradient centrifugation with sucrose or Optiprep, 
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ultrafiltration, high performance liquid chromatography, capturing by 
monoclonal antibodies against exosome-associated membrane proteins, such as 
tetraspannins CD9, CD63, CD81, CD82, epithelial cell adhesion molecule 
(EpCAM), and Ras-related protein 5 (Rab5). The antibodies can be combined with 
magnetic beads, chromatographic matrix, plates and microfluidic devices for 
separation [59].  Most the above-mentioned isolation methods provide a highly 
selective purification of exosomes. Furthermore, several techniques can then be 
used to characterize exosomes, including flow cytometry, nanoparticle tracking 
analysis, dynamic light scattering (DLS), western blot, mass spectrometry, and 
microscopy [60]. Exosomes can also be characterized on the basis of their protein 
compositions: typical exosomal markers are tetraspanins, TSG101, ALG-2 
interacting protein X (ALIX), flotillin 1, and Lysosomes associated membrane 
glycoprotein 2 (Lamp2). According to ExoCarta, a wide exosome database, there 
are currently around 8000 proteins and 194 lipids known to be associated with 
exosomes [61] (www.exocarta.org). 
 
1.7.2   Methods of drug encapsulation into exosomes 
 
The approaches investigated so far to incorporate drugs into exosomes can be 
classified into active and passive loading strategies. The formers include the use of 
mechanical (extrusion), chemical (incubation with or without permeabilization 
agents, like saponin or other detergents) or physical stimuli (sonication, 
electroporation, freeze and thaw cycles) to incorporate either small molecules 
(curcumin, paclitaxel, doxorubicin), RNAs or proteins (catalase, saporin) into 
purified exosomes [62, 63, 64, 65, 66, 67]. Even if demonstrated to be successful, 
these methods suffer from the great limitation of affecting vesicles structural 
composition and achieving very low drug encapsulation efficiency. 
Electroporation, in particular, acts by perturbing the exosomal membrane 
throughout the application of an electrical current, that results in the temporary 
formation of pores, allowing the diffusion of the drug in the vesicle. It is widely 
used to incorporate a broad spectrum of drugs into isolated exosomes, among which 
siRNA, miRNA, proteins and small molecules, leading to an increased loading 
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efficiency over the other methods. Nakase et al. have demonstrated that 
electroporation is highly effective in enhancing saporin encapsulation, as shown by 
in vitro cytotoxic assays, but the amount of exogenous protein loaded was 
calculated to be around only 0.1% [66, 68]. The passive loading strategies, on the 
other hand, are modeled on the incubation of exosomes/cells with free drugs, that 
do not compromise the vesicles membrane integrity but, similarly, enhance a very 
low cargo-incorporation [69, 70].  
 
1.7.3   Methods to confer targeting properties to exosomes 
 
As for cargo loading, surface decoration of exosomes with targeting moieties can 
be achieved through genetic engineering of donor cells. The first proof of concept 
of the applicability of this strategy was obtained by Alvarez-Ervitii et al., who used 
Lamp2b, a well characterized exosomal membrane protein, as anchor and fusion 
partner for targeting domain of interest. They demonstrated that acetylcholine 
receptor binding rabies viral glycoprotein (RVG) peptide could be displayed onto 
exosomes from dendritic cells and improve their delivery to target cells [65]. This 
seemingly simple yet effective engineering technique was also applied to other 
targeting ligands, such as iRGD peptide, that showed highly efficient 
drug delivery to αv integrin-positive breast cancer cells in vivo [71, 72], and for 
exosomes incorporation of tags and reporter proteins [73, 74]. However, despite the 
clear advantages that this method would achieve, such as an increased homogeneity 
of vesicles batches, surface structure preservation and reduced time-consuming 
work, a recent report demonstrated that, instead of sorting into exosomes, 
degradation of fusion proteins may occur when this approach is employed [73]. As 
an alternative, stable conjugation of targeting ligands to the surface of isolated 
exosomes can be realized using chemical linkers, with similar methods employed 
to functionalize synthetic particles and liposomes. Smyth et al., for instance, have 
reported that N-hydroxy succinimidyl ester reactive groups on exosomes, mostly 
comprising available N-termini and lysine residues of membrane proteins, can be 
stably linked to targeting ligands under biocompatible reaction conditions [75]. 
This conjugation has been shown to not change the physical characteristics of 
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exosomes nor their interaction with recipient cells. In addition, stearyl anchoring 
moieties have also been proposed and demonstrated to be effective in improving 
exosomes surface decoration with cell penetrating peptides [76].  However, the 
successful and stable modification of exosomes surface with targeting moieties is 
nontrivial. The reaction conditions must be strictly limited to avoid exosome 




Aim of the study 
 
Surgery represents the primary choice in the treatment of solid tumors, usually in 
combination with chemotherapy or radiotherapy cycles. Although conventional 
radio-chemotherapeutics have a broad spectrum of action and are partially effective 
in the treatment of many cancers, serious side effects severely limit their use, 
pharmacological dosage and number of cycles that can be given. In fact, they totally 
lack specificity and, as a result, patients are treated with levels of drug that are often 
sub-lethal to the cancer. These limitations have been partially overcome by the use 
of immunotherapies as combination therapies, that are certainly more specific in 
targeting cancer cells but can poorly penetrate into the tumor mass due to their 
dimensions and can induce cancer cells to develop drug resistance. In this context, 
many efforts are focused on the development of targeted and personalized therapies 
aimed at exploiting specific tumor pathways and receptors to selectively kill 
neoplastic cells. Compared to monoclonal antibodies, RIP toxins have many 
incremental advantages, such as the small dimensions and globular structure, the 
lack of a specific ligand domain and the direct cells killing property. The aim of 
this project is to develop two different therapeutic options, based on the plant toxin 
SAP, for the treatment of bladder cancer, whose application could also be extended 
to a broader range of solid tumors. In fact, we have selected targets expressed in 
multiple-tumor types that would widen disease indications and prevent tumor 
resistance caused by the emergence of antigen-loss variants. In particular, as a first 
approach we explore the therapeutic potential of a targeted protein-based strategy, 
in which small peptides are employed to specifically deliver SAP to cancer cells 
and tumor microenvironment. In parallel, we propose to couple the features of 
exosomes as drug delivery system with SAP activity. The biocompatible 
characteristics of exosomes, with suitable modifications, can increase the stability 
and efficacy of SAP therapeutics while enhancing cellular uptake and reducing 
potential in vivo immunogenicity. Overall, we expect to prepare a number of 
therapeutic options as large as possible to cope with intra- and inter- tumor 
heterogeneity. Synergistic coupling of high toxin activity to targeting peptides or 
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nanovesicles would provide novel strategies and useful tools to achieve major 
advancements for the treatment of heterogeneous diseases such as cancer.  
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2.   Materials and methods 
 
2.1 Cells culture 
 
Human bladder (RT4, RT112, 5637, HT1376), breast (MDA-MB 231, MDA-MB 
468, BT549, SKBR3) and glioblastoma (U87) cancer cell lines were obtained from 
American Type Culture Collection (ATCC) and maintained respectively in RPMI 
1640 (bladder) or DMEM medium (breast and glioblastoma) supplemented with 
10% FCS, 2 mM L-Glutamine and antibiotics (100 U/mL penicillin and 100 µg/mL 
streptomycine-sulphate). Human ECV304 bladder cancer cells were maintained in 
medium 199 supplemented with 10% FCS, 2 mM L-Glutamine and antibiotics (100 
U/mL penicillin and 100 µg/mL streptomycine-sulphate). Human SUM149 and 
SUM159 triple negative breast cancer cells were cultured in HAM-F12 medium, 
supplemented with 5% FCS, 2 mM L-Glutamine, antibiotics (100 U/mL penicillin 
and 100 µg/mL streptomycine-sulphate), insulin (2 µg/ml) and hydrocortisone (1 
µg/ml), 10 mM HEPES. Murine MB49 bladder cancer cells were cultured in 
DMEM medium, supplemented with 10% FCS, 2 mM L-Glutamine, antibiotics 
(100 U/mL penicillin and 100 µg/mL streptomycine-sulphate) and Sodium 
Pyruvate (1 mM). 
MB49 Luc cells stably expressing luciferase were generated by transduction with a 
3rd generation lentiviral vector carrying the luciferase gene. pLenti PGK V5-LUC 
Neo (w623-2) was a gift from Eric Campeau (Addgene plasmid # 21471). For 
lentivirus production, HEK293T cells were transfected with the CaCl2 method. To 
this end, a mix containing 10 µg of transfer vector, 6.5 µg of packaging vector ∆r 
8.74, 3.5 µg of Env VSV-G, 2.5 µg of REV, ddH2O to 450 µl, 50 µl of 2.5 M CaCl2 
and 500 µl of 2X HBS was added dropwise over a monolayer of HEK293T cells 
seeded on a 10 cm2 dish. After 16 hours, the medium was replaced; 24 hours later 
the medium containing virus particles was collected, filtered on a 0.22 µm filter and 





2.2 Flow cytometry analysis 
 
Cultured cell lines were detached by TripLE Express (Gibco) to preserve receptor 
integrity, washed with PBS containing 1% FCS and incubated with primary 
antibody (Ab) specific for human uPAR (Sekisui), PE-conjugated Ab specific for 
human anb3 (R&D System) and FITC-conjugated Ab specific for human 
anb6 integrins (NovusBio). For uPAR detection, cells were incubated with the 
primary Ab at 4° C for 1 h, followed by secondary antibodies conjugated to FITC 
for 30 min. For integrins detection, cells were incubated with the fluorescently 
labelled Ab at 4° C for 30 min. Stained cells were resuspended in 100 µL of PBS 
containing 1 % FCS. Secondary FITC-conjugated antibody only or isotype control 
stained cells were used as negative controls. Samples were run through an AccuriTM 
flow cytometer (BD Biosciences). All data were analysed by FCS Express and 
expressed as relative fluorescence intensity (RFI), calculated as follows: mean 
fluorescence intensity after mAb staining/mean fluorescence intensity after isotype-
negative control staining. 5637 and RT112 cells were cultured in 24-well 
microplates until 60% confluence. 24 hours later, the cells were treated with 
labelled exosomes (15 µg/well) and incubated at 37° C, 5% CO2 for 48 hours. Then, 
cells were detached by incubation with 0.01% trypsin for 5 min at 37° C, collected, 
washed with 1% FBS (in PBS) and subjected to flow cytometry analysis using 
AccuriTM flow cytometer. Analysis was done on 10,000 gated events per sample. 
 
2.3  Cell viability assay 
 
Cultured cell lines were seeded in 96 wells plates and incubated for 72 hours with 
scalar logarithmic concentrations of ATF-SAP WT, ATF-SAP KQ, pro-uPA-SAP, 
RGD-SAP, CYS-SAP or saporin alone (seed SAP). After 72 hours of incubation at 
37° C, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 
mg/ml in PBS) was added (0.5 mg/ml working concentration). After 1 hour 
incubation at 37° C, supernatants were removed and 100 µl/well of dimethyl 
sulfoxide were added to dissolve formazan crystals. Cell viability was assessed by 
measuring the absorbance at 570 nm and expressed as percentage to untreated 
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control. The toxic activity of the recombinant proteins was evaluated as IC50, shown 
as mean ± SD from three independent experiments. For the competition 
experiments, MDA-MB-468 cells were seeded in 96 well plates, exposed to 20 nM 
ATF-SAP in the absence or presence of increasing concentrations of uPA (4, 20, 
100 nM), PAI (4, 20, 100 nM) or uPA+PAI (100 nM + 100 nM), for 72 h. RGD-
SAP binding to an integrins was competed by exposing 5637 cells to 100 nM RGD-
SAP or 1 µM CYS-SAP in the presence of 5 µg/ml ACDCRGDCFCG peptide for 
24 and 48 hours. Residual cells viability was evaluated by MTT assay.  
 
2.4  Establishment of primary human bladder-derived fibroblasts culture 
 
Human bladder biopsies were obtained from men undergoing bladder surgery in 
agreement with informed consent. Cells were obtained through a primary explant 
technique. Briefly, the tissue was minced with a scalpel into small pieces (1–2 mm3) 
and washed in fresh medium to eliminate the excess of mucus or blood proteins. 
Tissue pieces were then placed on a dish for primary culture and incubated in 
MEM-Non-essential amino acids (100x, without L-Glutamine) (Lonza), 
supplemented with 1% FCS, antibiotics (100 U/mL penicillin and 100 µg/mL 
streptomycine-sulphate), 200 nM Hydrocortisone (Sigma), 10 nM Triiodothyronine 
(Sigma), 5 ng/ml Epidermal growth factor (Gibco, Life Technologies). The 
incubation was carried out for 3-5 days. Then the medium was changed at weekly 
intervals until a substantial outgrowth of cells was observed. The explants were thus 
removed and the cells transferred to a fresh dish. Cells were cultured for a maximum 
of 20 days. 
 
2.5  Immunofluorescence analysis 
 
ECV304 epithelial bladder cancer cells, skin and bladder-derived fibroblasts were 
seeded in sub-confluent conditions and grown overnight on glass coverslips. After 
24 hours, cells were quickly washed in PBS and fixed in 4% paraformaldehyde in 
PBS at room temperature for 30 min. After extensive PBS washing to remove the 
excess of paraformaldehyde, cells were permeabilized in 0.2% Triton and incubated 
 27 
in 10% donkey serum in PBS for 1 hour. Primary antibody incubation was 
performed for 1 hour at room temperature using: anti-human Fibroblasts Surface 
Protein (Abcam, working dilution 1:100 in 1% donkey serum, 0.1% Triton in PBS) 
or anti- human Actin a-Smooth Muscle (Sigma-Aldrich, working dilution 1:500 in 
1% donkey serum, 0.1% Triton in PBS). Fluorescent signal was detected by the use 
of Alexa488-conjugated secondary antibody (working dilution 1:500 in 1 % donkey 
serum, 0.1% Triton in PBS). Then, coverslips with stained cells were mounted on 
a microscope slide with VECTASHIELD Antifade Mounting Medium with DAPI 
(Vector Laboratories, Burlingame, CA, USA), carefully avoiding the formation of 
air bubbles. Fluorescent images were taken by using Axio Vision Imaging Software 
(Axiovision Rel 4.8®) on an Axio Imager M2 microscope (Carl Zeiss, Oberkochen, 
Germany). 
 
2.6  RNA extraction and quantitative analysis 
 
Total RNA from bladder and breast cancer cell lines was extracted using TRIzol 
LS Reagent (Invitrogen) according to the manufacturer’s recommended protocols. 
RNA was then retrotranscribed with High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems). A calibration curve was performed for each gene of 
interest to test primers and to determine the correct concentration of cDNA to use 
for quantitative Real Time. For primers used, see Table 1. Each cDNA sample was 
diluted with nuclease free water to obtain the correct amount (0.5 ng) in a volume 
of 12.5 µl. The mix for the primers was prepared as follows: 12 µl of SYBR green 
PCR master mix and 0.5 µl of primers (forward and reverse). The total reaction was 
set for 25 µl/well. Two complementary primers for each gene of interest were 
purchased from Eurofins. uPAR, uPA and LRP1 expression levels (indicated as 
“fold change” compared to healthy fibroblasts, used as a reference) were analyzed 






2.7  Preparation of RGD-SAP and CYS-SAP  
 
SAP fused with the C-terminus of respectively ACDCRGDCFCG or CGGSGG 
were prepared by recombinant DNA technology. For primers used, see Table 1. To 
place the ACDCRGDCFCG sequence upstream the SAP sequence, two 
complementary single strand oligonucleotides encoding the ACDCRGDCFCG 
sequence, flanked by NdeI and BamHI restriction sites at the 5′ and 3′ ends, 
respectively, were designed. They were annealed by heating to 95° C for 10 min in 
nuclease free water and slowly cooled to 25° C. The procedure produced a double-
strand DNA fragment with NdeI and BamHI cohesive ends ready for ligation. No 
further purification was used. A GGSSRSS sequence containing a BamHI 
restriction site was interposed between ACDCRGDCFC and SAP as a spacer and 
introduced to the N-term of the SAP encoding sequence by PCR amplification. This 
PCR product was digested with BamHI and EcoRI. To position the CGGSGG 
sequence, standard PCR was performed on SAP encoding gene with a forward 
primer including the CGGSGG sequence flanked by NdeI restriction site and a 
reverse primer including an EcoRI site. The NdeI site contains also the translation 
starting codon. The pET22b (+) vector (Novagen) was linearized with NdeI and 
EcoRI to clone the CYS-SAP sequence or with BamHI and EcoRI to clone SAP 
encoding sequence containing the spacer. The oligonucleotide encoding for the 
ACDCRGDCFCG sequence was then sub-cloned by linearizing the plasmid with 
NdeI and BamHI. The inserts were ligated into the linearized vectors overnight at 
16° C, forming the pET22b (+)-RGD-SAP (5′-NdeI-RGD-BamHI-GGSSRSS-
SAP-EcoRI-3′) and the pET22b (+)-CYS-SAP (5′-NdeI-CYS-SAP-EcoRI-3′) 
expression vectors. The 6xHis tag at C-terminus of each recombinant protein was 
maintained in order to allow the purification by affinity chromatography. Ligation 
products were used to transformed the E.coli strain DH5alpha (Invitrogen). The 
plasmid sequence was checked through analytical digestion and sequencing. 
The expression of RGD-SAP and CYS-SAP in transformed BL21(DE3) E.coli cells 
(Novagen) was induced for 3 hours at 37° C with IPTG 0.1 mM. Bacterial pellet 
from 1 L culture was resuspended in 15 ml of lysis buffer (Tris-HCl, 50 mM pH 
7.5 supplemented with a cocktail of protease inhibitor (Sigma-Aldrich). Soon after, 
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10 mM of imidazole, lysozyme 250 µg/ml and DNAse 20 µg/ml were added. The 
resuspended bacterial lysate was then incubated for 45 min on ice, sonicated on ice 
with the UW3100 Bandelin sonicator with 60% power for 2 min (1 second pulse / 
1 second pause) for 3 cycles and centrifuged at 4° C for 25 min at 11,000 rpm. The 
supernatant (total cell extract) was stored at -80° C before purification.  
 
2.8  Preparation of Lamp2b, CD9 and CD81-based constructs 
 
Lamp2b signal peptide (SP) and gene sequence, CD9 and CD81 cDNA sequences 
were amplified from HEK293-derived cDNA. To place the ACDCRGDCFCG 
peptide between SP and Lamp2b sequences, standard PCR was performed, using a 
forward primer specific for Lamp2b including a half of the peptide sequence, 
flanked by SpeI restriction site, and a reverse primer specific for the SP including 
the other half of the peptide, flanked by SpeI restriction site. The two fragments 
carrying the SpeI restriction sites were digested and ligated together to obtain SP-
RGD-Lamp2b product. NheI and SalI restriction sites were inserted respectively at 
N-terminus and C-terminus of the full construct (5′-NheI-SP-RGD-Lamp2b-SalI-
3′). The same restriction sites were also inserted at the N-terminus and C-
terminus of CD9 and CD81 encoding genes by PCR amplification. PCR 
amplification was also performed to position the RFP or SAP encoding genes 
downstream the Lamp2b or tetraspanins sequences. Cathepsin B specific Phe-Leu 
dipeptide (cleavage site, CS) or its non-specific variant Gly-Ser (nonactive cleavage 
site, NACS), flanked by two glycine as a spacer and SalI restriction site were 
included in RFP or SAP forward primers, flanked by the SalI restriction site.  A 
NotI containing primer was used as reverse. The sequences contain: 5′-NheI-SP-
RGD-Lamp2b-SalI-GFLG/GGSG-RFP/SAP-NotI-3′; 5′-NheI-CD9-SalI-
GFLG/GGSG-RFP-NotI-3′; 5′-NheI-CD81-SalI-GFLG/GGSG-RFP-NotI-3′. All 
the linearized constructs were sub-cloned downstream the CMV promoter into a 





2.9  Stable transgene expression 
 
5637 or HEK293 cells (2 x 106) were plated in a 10 cm2 dishes and incubated for 
24 hours. Plasmid DNA (total 8 µg/dish) and TransIT-X2 transfection reagent 
(Mirus) were diluted separately in serum- and antibiotic free medium and then 
mixed together in a 1:2 ratio. After 20 min incubation, the mixture was added 
dropwise over the cells monolayer. After 16 hours the medium was replaced and 
transfected cells were selected by G418 for fifteen days 
 
2.10   RGD-SAP and CYS-SAP purification 
 
Soluble RGD-SAP and CYS-SAP were purified from bacterial lysates by affinity 
chromatography using a HisPur™ NiNTA resin (TermoFisher Scientific) 
equilibrated in Tris-HCl 50 mM pH 7.5 supplemented with 10 mM imidazole. For 
recombinant protein elution 1 M imidazole was used. An ion exchange 
chromatography on SP-Sepharose XL column (HiPrepSP XL 16/10, GE Healthcare 
Life Sciences) was then performed for further purity achievement. 1 M NaCl was 
added to the product of ion exchange. The proteins were then concentrated using 
10 kDa cut off Amicon centrifugal Filters (Millipore-Sigma). All solutions used in 
purification steps were prepared with sterile and endotoxin-free water (S.A.L.F. 
Laboratorio Farmacologico SpA, Bergamo, Italy). Protein concentration was 
measured using the BCA Protein Assay DC™ Kit (BioRad). Protein purity and 
identity was checked by SDS-PAGE and Coomassie blue staining and Western 
blotting. 
 
2.11   Protein extraction, Coomassie blue staining and western blot analysis  
 
Cells were washed twice with cold PBS, collected by scraping and centrifuged 5 
min at 1200 rpm. Cells were lysed for 30 min on ice in ice-cold buffer (150 mM 
NaCl, 2 mM NaF, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 1 mM PMSF, 75 
mU/ml aprotinin -Sigma-, 50 mM Tris-HCl, pH 7.5) containing 1 % TX-100 and a 
cocktail of proteinase inhibitors (Sigma-Aldrich). Cell lysates were centrifuged at 
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10000 xg at 4° C for 10 min. Proteins contained in the supernatant were quantified, 
resuspended in sample buffer (62.5 mM Tris-HCl (pH = 6.8), 2% SDS, 10% 
glycerol, 0.002% bromophenol blue, 5% 2-mercaptoethanol) and boiled at 95°C for 
5 minutes. Proteins were separated via SDS-PAGE. All the SDS-PAGE were run 
under reducing conditions unless stated otherwise. For Coomassie blue staining, 
acrylamide gels were incubated in a Coomassie blue solution (0.1% Coomassie 
Brilliant Blue R-250, 50% methanol and 10% glacial acetic acid) for 1 hour; then a 
5% acetic acid solution and 45% of methanol incubation was used to detect the 
protein of interest. For western blot analysis, proteins were transferred onto a 
nitrocellulose membrane, incubated with 5% non-fat powdered milk in TBS-T 
(0.5% Tween-20) for 1 hour and then with the following antibodies: Saporin 
(1:5000), Caspase 3 (1:2000, Abcam), b-actin (1:10000, Sigma), Flotillin (1:5000, 
Sigma), Alix (1:800, Santa Cruz Biotechnology), CD63 (1:1000, BD Biosciences), 
CD9 (1:1000, BD Biosciences), CD81 (1:1000, BD Biosciences). Secondary 
horseradish peroxidase conjugated antibodies (anti-mouse/rabbit IgG HRP-linked 
whole antibody donkey, GE Healthcare) were used and immunoreactive bands were 
visualized by using the Enhanced Chemiluminescence (ECL) (Merck Millipore).  
 
2.12   Ex vivo studies 
 
A sub-confluent 5637 or RT112 bladder cancer cells were plated in 10mm dish, 
detached in exponentially growth conditions and resuspended in serum and 
antibiotics free RPMI. 7-week-old NSG mice were subcutaneously injected with 
1x106 cells in the left flank. Tumor growth was monitored with caliper. Animals 
were sacrificed when the tumor started to grow exponentially. The tumor mass was 
explanted, minced and dissociated with Trypsin (0.25 mg/ml in RPMI) at 37°C for 
10 min to obtain single-cell suspension. Cells were then further mechanically 
disaggregated by pressing the pellet through a cell strainer (70 µm) and treated with 
DNAse (100 µg/ml, Sigma-Aldrich) and ACK lysing buffer (Lonza) to remove red 
blood cells. Single cells were finally washed extensively with medium 
supplemented with FCS 10%, 2 mM L-Glutamine and antibiotics (100 U/mL 
penicillin and 100 µg/mL streptomycine-sulphate) and dispersed into 10 mm 
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dishes. After 1 week of in vitro culture, cells were collected, counted and reinjected 
in the left flank of 7weeks old NSG mice (1 x 106 cells/mouse). After mice sacrifice 
and cells recovery from tumor mass dissociation, flow cytometry analysis to 
monitor uPAR expression and cell killing assay with ATF-SAP were performed as 
described above. 
 
2.13   In vivo studies 
 
Studies on animal models were approved by the the Institutional Animal Care and 
Use Committee (Institutional Animal Care and Use Committee, IACUC) and 
performed according to the prescribed guidelines. Subcutaneous syngeneic mouse 
model: 7 weeks old C57BL/6 female mice (Charles River, Calco, Italy) were 
injected in the left flank with 5 x 105 (experiment 1) or 3 x 105 (experiment 2) MB49 
living cells; 5 days later, mice were treated with RGD-SAP or CYS-SAP solutions 
(200 µl). The treatment was repeated every 5 days for 3 times. Subcutaneous 
xenograft mouse model: 7-week-old CD1 nude female mice (Charles River, Calco, 
Italy) were injected in the left flank with 1 x 106 RT112 living cells; 10 days later, 
mice were treated with ATF-SAP, RGD-SAP or ATF-SAP + RGD-SAP solutions 
(200 µl). The treatment was repeated every 5 days for 3 times. All toxins, diluted 
with sodium chloride, were administered intravenously (i.v.). Orthotopic syngeneic 
mouse model: 7 weeks old C57BL/6 female mice (Charles River, Calco, Italy) were 
anesthetized with Ketamine/Xylazine (80/10 mg/kg) and catheterized with PE50 
catheters (BD Biosciences). The catheters were lubricated with 2.5 % lidocaine-
containing gel (Luan). To enhance tumor engraftment, bladder was pretreated with 
100 µl of 0.1 mg/mL poly-L-lysine (PLL, mol. wt. 70,000–150,000) (Sigma 
Aldrich), which was injected transurethrally and kept into the bladder for 30 min, 
as described by Loskog et al. 2005. The bladder was then washed with PBS before 
the instillation of 100 µL of 5 x 104 MB49 Luc. Tumor cells were kept in the bladder 
for 30 min. After the final incubation the catheters were removed. On day 7 after 
injection, mice were treated with RGD-SAP (200 µl) every 5 days for 3 times 
(experiment 1) or with MMC in PBS (50 µg) every 4 days for 2 times and RGD-
SAP every 5 days for 3 times. MMC treatment was given transurethrally in 
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anesthetic conditions (Ketamine/Xylazine) and kept in the bladder for 1 hour. 
Before MMC treatment, urine was squeezed out from the bladder and the bladder 
was washed with PBS. Subcutaneous tumor growth was monitored daily by 
measuring tumor volumes with calipers as described previously. Tumor volumes 
are shown as mean ± SD (4 animals/group experiment 1; 6 animals/group 
experiment 2) and calculated as follows: r1 × r2 × r3 × 4/3 π, where r1 and r2 are the 
longitudinal and lateral radii, and r3 is the thickness of tumors protruding from the 
surface of normal skin. Orthotopic tumor engraftment and growth was monitored 
once a week by in vivo bioluminescence imaging (IVIS). Tumor bioluminescence 
was calculated as total photon flux and shown as mean ± SD. Mice weight was 
recorded every 2 days and their health/behaviors monitored daily. Animals were 
euthanized when tumors reached 10 mm in diameter, became ulcerated or a 20% 
weight loss was detected. In the case of the orthotopic model, mice were euthanized 
when the bioluminescence intensity (BLI) reached 109 value, in case of a sudden 
drop of the BLI signal, in case of 20% weight loss or animal lethargy.  
 
2.14   Blood sample collection and biochemical parameters analysis 
 
Blood samples were collected from the retroorbital plexus of anesthetized mice. 
Anesthesia was induced by placing each mouse in an inhalation chamber with 4 % 
isoflurane regulated with a calibrated vaporizer. Blood samples were left at room 
temperature for at least 30 min before being processed, then centrifuged (3,000 rpm, 
10 min) for serum separation. Serum Albumin, aspartate transaminase (AST), 
alanine transaminase (ALT), creatinine and urea were determined by using an 
automated analyzer (ScilVet ABC plus and Idexx Procyte analyzers) according to 








2.15   Exosomes and microvesicles isolation 
 
Human embryonic kidney cell line HEK293T (5 x 106) were seeded on 150 mm 
dishes in DMEM medium supplemented with 10% FCS, 2 mM L-Glutamine and 
antibiotics. 72 hours after incubation, the cell culture medium was collected and 
centrifuged (1500 rpm) for 25 min to remove cell debris. For exosomes isolation, 
the obtained supernatant was filtered through 0.22 µm filter before 
ultracentrigugation at 150,000 xg for 2 hours at 4° C (Beckman Coulter). The 
exosomes containing pellet was resuspended in PBS. For microvesicles isolation, 
cell debris-free supernatant was centrifuged at 10,000 xg for 30 min at 4° C. The 
microvesicles containing pellet was resuspended in PBS. Concentration of isolated 
exosomes and microvesicles was calculated as protein concentration, which were 
determined using a Pierce BCA protein assay kit (Thermo Scientific). 
 
2.16   Dynamic light scattering (DLS) analysis 
 
DLS analysis was performed with a Zetasizer nanoseries instrument (Malvern 
Nano-Zetasizer = 532 nm laser wavelength). The exosome size data refers to the 
scattering intensity distribution (z-average). Exosomes were re-suspended in PBS 
at a concentration of 1 ng of protein/ml. Samples were manually injected into the 
sample chamber at room temperature. Each sample was measured in triplicate with 
an acquisition time of 30 s. 
 
2.17   Nanoparticle tracking analysis (NTA) 
 
NTA was performed by an expert EV laboratory (Exosomics Siena S.p.A, Siena) 
in order to provide a validation of the results. NTA was performed using a 
NanoSight LM10-HS microscope (NanoSight Ltd., Amesbury, UK). For the 
analysis, exosomes were diluted in 50  µl of PBS and concentrations adjusted, if 
necessary, in order to specifically fit the optimal working range (20–50 particles 
per frame) of the instrument. Three 60-s videos were recorded under the flow mode 
for each sample with camera level set at 16 and detection threshold set at 10. At 
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least 200 completed tracks per video were collected. The camera level and overall 
settings were selected as optimal for the accurate detection of exosome-sized 
nanoparticles following the manufacturer recommendations and as confirmed 
during instrument calibration. Videos were analyzed with NTA software version 
2.3 to determine the mean, mode and estimated concentration of measured particles 
with corresponding standard error. The NanoSight system was calibrated with 
polystyrene latex microbeads of 50, 100, and 200  nm (Thermo Scientific Waltham, 
MA, USA) prior to analysis and auto settings were used for blur, minimum track 
length and minimum expected particle size. 
 
2.18   Transmission electron microscopy (TEM) analysis 
 
Preparation of samples for TEM analysis was performed using the method 
described by Théry et al. [59]. HEK293-derived exosomes were mixed with an 
equal volume of 4% PFA and deposited by airfuge onto Formvar/Carbon coated 
EM grids (Ted Pella, Redding, CA, USA). Samples were contrasted and embedded 
by treatment with uranyl-oxalate solution (Electron Microscopy Science, Hatfield, 
PA, USA), pH 7, for 5  min, followed by methyl-cellulose-uranyl-acetate (Sigma, 
Saint Louis, MO, USA) on ice for 10  min. LEO 912AB Omega electron microscope 
(Carl Zeiss NTS, Oberkochen, Germany) was used for image analysis. 
 
2.19   Fluorescent labelling of exosomes and in vitro uptake tracing  
 
Exosomes isolated from cell culture media were resuspended in PBS and then 
combined with a PBS solution containing VybrantTM DiO (1 µl for 100 µg 
exosomes, Molecular Probes, Eugene, OR, USA). The sample were incubated at 
37° C for 30 min (protected from light) in stirring conditions and then passed 
through Exosome spin colums MW 3000 (Invitrogen) to remove any incorporated 
dye. PBS containing dye only was used as negative control. The samples were then 
ultracentrifuged (150,000 xg, 2 hours at 4° C) and the pellet resuspended in PBS. 
For the in vitro tracing assay, fibroblasts were seeded (up to 50-60% confluence) in 
a 24 multiwell plate and incubated at 37° C with 5 % CO2. 24 hours later, labelled 
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exosomes (5, 10 or 20 µg/ well) were added to recipient cells. Exosomes uptake 
was observed and evaluated after 24, 48 and 72 hours via fluorescent microscopy.  
 
2.20   Exogenous protein encapsulation into isolated exosomes 
 
HEK293 derived-exosomes were resuspended with SAP in 1 M Na2CO3 pH 11.5 
or PBS and incubated 30 min at 37° C. The amount of exosomes used was 
calculated as protein concentration. A ratio of 1 µg exosomes (EXO): 1.5 µg SAP 
was used to enhance the exogenous protein encapsulation. pH was then neutralized 
and the sample filtered by centrifugation through Exosome spin colums 100 KDa 
MWKO (Merk-millipore) to remove any incorporated protein and washed with 
NaCl 150 mM to reduce protein aggregation. SAP or exosomes alone were used as 
negative controls. 
 
2.21   Statistical analysis 
 
All in vitro experiments were performed at least in duplicate. Mouse experiments 
were performed using at least 4 mice per treatment group. When appropriate, 
statistical significance was determined using a 2-tailed Student’s t test. For tumor 
growth analyses, we performed one-way ANOVA statistical analysis. Survival 
curves were compared using the log rank test. Tests symbols mean: *p < 0.05; **p 

































CYS-SAP F 5’-atcccatatgtgcggcggcagcggcggcgtgaccagcattaccctgga-3’ 
SAP R 5’-atccgtcgactttcggcttgccc-3’ 
SP-RGD-Lamp2b-RFP 
SP F 5’- ataggctagcggtcgccaccatggtgtgcttccgcctct-3’ 
SP R 5’-atccgcggcaatcgcatgcctcgagtgcataagaccgcacagctc-3’   
Lamp2b F 5’-atccgcggcgattgcttttgcggtactagtttggaacttaatttgacagattc-3’ 
Lamp2b R 5’-atccgtcgactgcagagtctgatatccagcata-3’ 
RFP/SAP CS/NACS 
RFP-CS F 5’-tgcagtcgactggctttcttggaatggcctcctccgagaacg-3’ 
RFP- NACS F 5’-tgcagtcgactggcggttctggaatggcctcctccgagaacg-3’ 
RFP R 5’-agtcgcggccgctacaggaacaggtggtggc-3’ 
SAP-CS F 5’-tgcagtcgactggctttcttggaatggtcacatcaatcacattag-3’ 
SAP-NACS F 5’-tgcagtcgactggcggttctggaatggtcacatcaatcacattag-3’ 
SAP R 5’-atgcggccgcctactttggtttgcccaaatac-3’ 
CD9/CD81 
CD9 F 5’-ataggctagcgccaccatgccggtcaaaggaggca-3’ 
CD9 R 5’-atccgtcgactggaccatctcgcggttcctg-3’ 
CD81 F 5’-ataggctagcgccaccatgggagtggagggctgc-3’ 
CD81 R 5’-atccgtcgactggtacacggagctgttccgg-3’ 
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3.   Results I 
 
This first section of results focuses on the design and production of SAP based 
recombinant proteins carrying a tumor targeting moiety in their structure. The 
identification of over-expressed antigens on cancer cells surface allows a highly 
efficient molecular targeting, which enables the delivery of SAP enzymatic activity 
specifically to malignant cells. 
 
3.1 uPAR over-expression associates with a stage II muscle invasive bladder 
cancer and triple negative breast cancer phenotypes 
 
uPAR is known to exert an important role in tumor progression; there are many 
evidences of the positive correlation between uPAR levels and patient poor 
prognosis and overall survival [18]. With the aim to verify the clinical relevance of 
uPAR as a target, we firstly analyzed its gene and protein expression on a panel of 
bladder and breast cancer cell lines different in staging, grading and invasiveness 
(Fig. 1). Heterogeneous levels of this receptor were found in all the analyzed cell 
types: as regards for bladder cancer, a no or poor expression was detected in stage 
I superficial (RT4) and stage III muscle invasive cells (HT1376, ECV304), while a 
modest to evident overexpression was found in stage II bladder cancer cell lines 
RT112 and 5637. On the other hand, among the TNBC cells analyzed, 3 out of 4 
(MDA-MB-468, BT549 and SUM149) were highly uPAR positive, in contrast with 
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Fig. 1 uPAR espression in bladder and breast cancer cell lines. Bladder and breast cancer cell 
lines resembling respectively different stages (RT4 -T1 superficial-, RT112 and 5637- T2 muscle 
invasive-, HT1376 and ECV304 -T3 muscle invasive-) and subtypes (MDA-MB-468, BT549, 
SUM149, SUM159 -TNBC-, SKBR3 -HER2+-) were analyzed by quantitative PCR (see “Materials 
and Methods”) for uPAR gene expression (a) and by flow cytometry for uPAR protein expression 
(b and c). uPAR protein expression is shown as histogram plots (b) and Relative Fluorescence 
Intensity (RFI) (see “Materials and Methods”) (c). SKBR3 HER2+ breast cancer cell line was used 


































































































































3.2 ATF-SAP chimera  
 
After verifying the presence of uPAR on cancer cell lines in vitro, we took 
advantage of a uPAR-directed ATF-SAP chimera as a prototype of a tumor 
targeting toxin [30, 31]. This fusion protein is composed by SAP fused to the 
amino-terminal fragment (ATF) of human urokinase-type plasminogen activator 
(uPA), the natural ligand of uPAR. The insertion of a targeting moiety at the N-
terminal of the toxin allows its delivery specifically to uPAR expressing cells, thus 
limiting potential off-target effects. ATF-SAP coding sequence was cloned into a 
pPICZ vector for yeast expression and its production and purification was 
optimized in the methylotrophic yeast Pichia pastoris and scaled up in bioreactors 
[31]. The yeast system was demonstrated to be a suitable platform for the 
expression of recombinant proteins according to Lombardi et al. [77], allowing 
protein post-translation modifications, production and secretion of toxic SAP 
chimera. A catalytically inactive mutant (ATF-SAP KQ) was produced as a control 
[31]. 
 
3.2.1 ATF selectively delivers SAP toxin to uPAR overexpressing bladder and 
triple negative breast cancer cells 
 
In order to characterize the in vitro biological activity of the uPAR targeting 
chimera, uPAR+ and uPAR- bladder and breast cancer cell lines were incubated 
with scalar logarithmic concentrations of the toxin (Fig. 2).  As expected, ATF-SAP 
WT efficiency in killing cells was proportional to uPAR levels, impairing cell 
viability in a dose-dependent manner and in a higher significant extent compared 
to seed SAP, the untargeted control. In addition, cell death was unambiguously due 
to the presence of SAP enzymatic activity, as its catalytically inactive mutant ATF-
SAP KQ failed to exert any effect. Accordingly, it is worth of noticing that ATF-
SAP WT was not able to kill cells expressing low or undetectable uPAR levels 
(stage I and III bladder cancer and HER2+ breast cancer cell lines), meaning that a 
higher concentration of chimera is needed to reach an IC50, which results in a loss 
of receptor specificity.  
 41 









































Fig. 2 Cytotoxic activity of ATF-SAP on bladder and breast cancer cells. ATF-SAP activity and 
target specificity were evaluated on RT4, RT112, 5637, HT1376 and ECV304 bladder cancer cell 
lines (a) and on MDA-MB-468, SUM149, SUM159, BT549 TNBC and HER2+ SKBR3 breast 
cancer cell lines (b). Cells were incubated for 72h with scalar logarithmic concentrations of the toxin 
and cell viability was analyzed by MTT assay. The untargeted seed SAP and the catalytically 
inactive mutant ATF-SAP KQ were used as controls. The IC50 from three different experiments is 
reported as mean ± SE (Table 2 and 3). 
 
Table 3.  ATF-SAP chimeras and SAP activity on breast cancer cells 
                                                 Toxins cytotoxic activity (IC50a) in nM): 





MDA-MB 468 3 3.2±3  >1000 170±39 
BT549 3 13±6 >1000 70±14 
SUM149 3 12±11 >1000 125±106 
SUM159 3 >1000 >1000 >1000 
SKBR3 3 >1000 >1000 825±247 
a) IC50, the half maximal inhibitory concentration (mean±SE); b) n, number of 
independent experiments (each in triplicate). 
MDA-MB-468
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Table 2.  ATF-SAP chimeras and SAP activity on bladder cancer cells  
                                                Toxins cytotoxic activity (IC50a) in nM): 






5637 3 3.5±2 >1000 100±35 
RT4 3 >1000 >1000 150±35 
RT112 3 14.5±8  >1000 1000±0 
HT1376 3 47.5±3  >1000 150±0 
ECV 3 >1000 >1000 >1000 
a) IC50, the half maximal inhibitory concentration (mean±SE); b) n, number of 
independent experiments (each in triplicate). 
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On the basis of these results, we can conclude that stage II muscle invasive bladder 
cancer and TNBC represent good models to test ATF-SAP biological activity; 
furthermore, ATF targeting domain is absolutely required to increase the toxin 
selectivity on uPAR+ cells in in vitro assays. 
 
3.2.2 ATF-SAP internalization route is cell specific 
 
Next, we investigated the potential off-tumor toxicity of ATF-SAP by exploiting a 
non-tumoral cell line, such as healthy human skin derived fibroblasts. Due to their 
implication in physiological wound healing processes, fibroblasts are expected to 
express uPAR on their surface. In fact, as shown in Fig. 3a, high levels of uPAR 
were detected on these cells. Therefore, we wondered whether they were also 
sensitive to the activity of ATF-SAP. Notably, fibroblasts viability resulted 
unaffected by the toxin (Fig.  3c). To further corroborate their lack of sensitivity to 
the chimera and to validate bladder cancer as a candidate target for the proposed 
therapy, we extracted primary bladder-derived fibroblasts from a human bladder 
biopsy and, after immune-fluorescence characterization for typical fibroblasts 
markers, analyzed them for uPAR expression (Fig. 3a, b). Similarly to skin 
fibroblasts, even if a high uPAR positivity could be detected, bladder fibroblasts 
were spared by ATF-SAP, that resulted completely ineffective (Fig. 3c).  
This unexpected behavior was also noticed on MDA-MB 231 breast cancer cell 
line, which, in spite of displaying a high uPAR expression, were not sensitive to the 
activity of ATF-SAP (Fig. 3a, c). These data suggest that in some cases uPAR 
expression is not the sufficient condition to mediate ATF-SAP toxicity.  
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a.   b.           
 
 










Fig. 3 ATF-SAP activity on fibroblasts and MDA-MB-231 cancer cell line. (a) uPAR expression 
on skin and bladder-derived fibroblasts as well as breast cancer MDA-MB-231 cell line was 
analyzed by flow cytometry and expressed as histogram plots (upper panel) and Relative 
Fluorescence Intensity (RFI) (see “Materials and Methods”) (lower panel). The dashed line 
represents the threshold arbitrarily defining positive expression (RFI=2). b. Molecular profile of 
skin and bladder-derived fibroblasts. Human skin- and bladder-derived primary fibroblasts were 
analyzed by immunofluorescence for the expression of Fibroblasts Surface Antigen (SFA) and alpha 
Smooth Muscle Actin (aSMA). ECV304 epithelial bladder cancer cell line was used as negative 
control. Nuclei were stained with DAPI (blue). (c) ATF-SAP toxic activity was evaluated after 72 h 
incubation and compared to the untargeted seed SAP. Results from one representative experiment 
are shown as mean ± SD. Three independent experiments were performed for each assay. 
 
3.2.3 ATF-SAP internalization does not rely on uPAR natural ligands nor on 
uPAR cofactor LRP1 
 
Hence, we sought to determine if some other factor implicated in the urokinase 
plasminogen activation system is also involved in toxin internalization. To this 
purpose, we analyzed by Real-Time PCR the mRNA levels of LRP-1 (low density 
lipoprotein receptor related protein 1), known to be important not only in uPAR 
endocytosis and turnover on cell surface but also for SAP receptor mediated 
SFA
!SMA
Skin fibroblasts Bladder fibroblasts ECV
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internalization [51, 52, 55, 77]. Unexpectedly, we could observe LRP1 to be highly 
expressed by fibroblasts, but not by MDA-MB-231 cells (Fig. 4a). Analogously, 
we found ATF-SAP sensitive cells to have very low or undetectable LRP1 levels. 
In order to exclude any post transcriptional regulation of the above-mentioned 
transcript, we also confirmed this result by measuring LRP1 at a protein level by 
flow cytometry analysis (Fig. 4b). Such observation suggests that LRP1 seems not 
to be an essential cofactor for ATF-SAP-bound uPAR internalization. 











b.                       c.           
 
              
Fig. 4 LRP1 expression in bladder and breast cancer cell lines. Skin fibroblasts, bladder and 
breast cancer cell lines respectively resembling different stages (RT4 -T1 superficial-, RT112 and 
5637- T2 muscle invasive-, HT1376 and ECV304 -T3 muscle invasive-) and subtypes (MDA-MB-
468, MDA-MB-231, BT549, SUM149, SUM159 -TNBC-, SKBR3 -HER2+-) were analyzed by 
qPCR (see “Materials and Methods”) for LRP1 gene expression (a) and flow cytometry for LRP1 
protein expression  (b). LRP1 protein expression is expressed as histogram plots (b, left panel) and 
RFI (see “Materials and Methods”) (b, right panel). The dashed line represents the threshold 
arbitrarily defining positive expression (RFI = 2). 
 
Then, we investigated if the uPA amount produced by the same cell types is able to 
sequester its receptor from the ATF-SAP recognition and binding. To achieve this 
goal, we firstly analyzed its mRNA levels (Fig. 5a), but no differential uPA 
















































































































detected. Moreover, to deeper clarify whether high levels of uPA would compete 
with ATF-SAP for receptor binding and reduce the toxin uptake, we assessed the 
ability of ATF-SAP to be internalized in the presence of increasing concentrations 
of uPA and uPA inhibitor plasminogen activator inhibitor (PAI-1). The latter has 
been demonstrated to covalently bind and inhibit the proteolytic activity of uPAR-
bound uPA, promoting LRP1 association and internalization of the complex [52]. 
As shown in Fig. 5b, ATF-SAP cytotoxicity remained unchanged, meaning that 
there is no competition with uPA for receptor binding. Finally, as a proof of 
concept, aiming at demonstrating that ATF-SAP endocytosis relies on a peculiar 
uPA:PAI-1-LRP1-independent pathway, we used, for internalization comparison, 
a SAP-based compound in which SAP is chemically conjugated to the entire pro-
uPA ligand (pro-uPA-SAP) [55]. In this setting, both fibroblasts and MDA-MB-
231 were efficiently killed by the conjugation product, indicating that uPAR can be 
efficiently bound and internalized in cells refractory to ATF-SAP (Fig. 5c).  
a.                                                                        b.        
               
c.                                                                                   







Fig. 5 uPA expression in bladder and breast cancer cell lines. (a) uPA gene expression (see 
“Materials and Methods”) was analyzed in skin fibroblasts, bladder and breast cancer cell lines 
respectively resembling different stages (RT4 -T1 superficial -, RT112 and 5637 - T2 muscle 
invasive-, HT1376 and ECV304 - T3 muscle invasive-) and subtypes (MDA-MB-468, MDA-MB-
231, BT549, SUM149, SUM159 -TNBC-, SKBR3 -HER2+-). (b) MDA-MB-468 cells were 
incubated with ATF-SAP 20 nM in the presence of equal or increasing concentrations of uPA or 
PAI. (c) Comparison of pro-uPA-SAP and ATF-SAP toxic activity on fibroblasts and MDA-MB-
231 cells. The effect on cell viability was evaluated after 72h by MTT assay. Seed SAP was used as 
untargeted control. Results from one representative experiment are shown as mean ± SD. Three 






































































































































































3.2.4 Evaluation of uPAR expression stability and ATF-SAP activity on stage 
II bladder cancer cells after implantation in mice 
 
Since tumor propagation via prolonged cell culture generally may promote loss of 
surface antigens, we investigated if uPAR expression is stably maintained even with 
multiple serial tumor implantations in mice, in order to predict ATF-SAP efficiency 
in an in vivo environment. To this aim, stage II bladder cancer cells were 
subcutaneously injected and grown in the flank of NSG mice for two times and, 
once explanted, analyzed for uPAR expression and ATF-SAP sensitivity. As shown 
in Fig. 6, a minimal downregulation of receptor was observed and ATF-SAP dose-
dependent biological activity was in line with previous results, further supporting 
the use of stage II bladder cancer cell lines as suitable in vivo models to test the 
chimera pharmacological efficacy.          
 a. 
 
          
                                        
 b.                                                 c.        
   
 
Fig. 6 Cytotoxic activity of ATF-SAP on ex vivo bladder cancer cells. (a) Schematic 
representation of the experimental design. RT112 and 5637 cells were subcutaneously injected in 7-
week-old NSG immunocompromised mice serially for two times. (b) After the second implantation, 
established tumors were minced and tumor cells analyzed for uPAR expression by flow cytometry. 
Results are shown as RFI (see “Materials and Methods”) (left panel). The dashed line represents the 
threshold arbitrarily defining positive expression (RFI=2). (c) Explanted cells were then incubated 
for 72h with ATF-SAP and cell viability was evaluated by MTT assay (right panels). Seed SAP was 
used as untargeted control. Results from one representative experiment are shown as mean ± SD. 
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3.2.5   Development of an an-integrins targeting SAP- based recombinant 
protein: RGD-SAP 
 
With the purpose to develop a toxin based-system able to target both cancer cells 
with epithelial origin and tumor microenvironment, we designed and produced in 
parallel a recombinant protein in which the effector SAP is fused to the 
ACDCRGDCFCG peptide, containing an Arginine-glycine-aspartic (RGD) motif. 
Such peptide can recognize with a certain affinity integrins expressed both on tumor 
cells and tumor neovasculature, therefore our aim is to extend the application of 
this targeting strategy to most solid tumors. Owing to the significantly smaller size 
of the ACDCRGDCFCG peptide compared to ATF, we chose the E. Coli bacteria 
system for RGD-SAP production. As for ATF-SAP, we used recombinant DNA 
technology to prepare the recombinant product, cloning the sequence into a pET22a 
plasmid for E. coli expression. A non-targeting SAP (CYS-SAP) variant carrying 
an N-terminal CGGSGG peptide was designed and produced in parallel. Both 
proteins carry a C-terminal histidine tag, which was exploited to enhance both 
affinity chromatography purification and endosomal escape of the toxin into 
recipient cells (Fig. 7). 
 a. 
                                                      
 b.  
                                                  
 
Fig. 7 Designing and optimization of recombinant proteins expression in E. Coli. (a) Schematic 
representation of RGD-SAP and CYS-SAP recombinant proteins. The RGD (ACDCRGDCFCG) 
targeting and CYS (CGGSGG) -containing non-targeting peptides were inserted at the N-terminus 
of SAP. A histidine (H)-tag was inserted at the C-terminus to aid in the purification of the 
recombinant proteins. (b) Proteins production was monitored by western blot with anti-
SAP antibody upon IPTG (+) induction of E. Coli bacteria; not induced bacteria (-) were used as 



























After the optimization of induction, temperature, time and IPTG concentration for 
the production of the SAP-based proteins, affinity, ion exchange chromatographic 
steps and dialysis were performed in order to obtain pure products (Fig. 8, 9, 10).  
As shown by western blot analysis, a single band of 30 kDa could be detected when 
RGD-SAP was run under both reducing and non-reducing conditions, as expected 
for monomers, excluding the formation of inter-chain disulfide bonds, owing to the 
ACDCRGDCFCG domain, and suggesting that this construct does not undergo 
degradation. In contrast, a double sized product could be detected for CYS-SAP, 
indicating that inter-chain disulfide bonds are likely formed between the N-terminal 
cysteines of this recombinant protein (Fig. 10). The final yield of the products was 
300 µg per liter of bacterial culture. 
a.               






                   
 
Fig. 8 SAP-recombinant proteins purification by affinity chromatography. RGD-SAP (a) and 
CYS-SAP (b) recombinant proteins were purified by affinity chromatography using a Ni-NTA resin 
for His-tagged proteins (left). The green line indicates the increasing levels of imidazole; the blue 
line indicates the absorbance at 280 nm, which correlates with the presence of proteins. Fraction 
corresponding to the main elution peak were analyzed by western blot with anti-SAP antibody 
(upper right) and Coomassie blue staining (lower right) for protein detection and purity 
































               
          
b. 
                         
 
 
Fig. 9 SAP-based recombinant proteins purification. RGD-SAP (a) and CYS-SAP (b) 
recombinant proteins derived from positive fractions obtained from affinity chromatography were 
pooled and further purified by ion exchange chromatography using a Hiprep sp XL column (left). 
The green line indicates the increasing levels of NaCl; the blue line indicates the absorbance at 280 
nm, which correlates with the presence of proteins; The fractions corresponding to the main elution 
peak were analyzed by western blot with anti-SAP antibody (upper right) and Coomassie blue 
staining (lower right) for protein detection and purity determination. 
 
                               
Fig. 10 Sap based recombinant proteins final products after purification steps. Positive 
fractions from ion exchange chromatography were pooled and dialyzed; products isolation was 
analyzed by western blot using anti-SAP antibody. SDS-PAGE was performed under reducing 
(RED, left) and non-reducing (NOT RED, right) conditions in order to evaluate the presence of 




















































3.2.6 RGD specifically deliver SAP toxin to an-integrins expressing cells  
 
RGD motif has been demonstrated to specifically recognize and bind an-integrins 
(anb3, anb5 and anb6) with different affinities [25]. Besides being overexpressed 
on the surface of endothelial cells, these integrins are also highly present on a 
variety of tumor cells [12, 26, 27, 28]. Therefore, with the purpose to identify the 
best model to validate in vitro the targeting efficiency of RGD-SAP, we analyzed 
different cancer cell lines for anb3 and anb6 integrins expression by flow 
cytometry. We detected high anb3 levels only on U87 glioblastoma cell lines. In 
contrast, RT4, RT112 and 5637 bladder and MDA-MB-468 breast cancer cells 
showed a slight positivity for anb6. Remarkably, healthy fibroblasts do not express 
any of the two integrins of interest (Fig. 11a). Next, to both determine whether 
RGD-SAP preferentially binds to one particular integrin and to prove its in vitro 
activity, cells were incubated for 72 h with scalar logarithmic concentrations of 
RGD-SAP or CYS-SAP and the effect on cells viability was evaluated by MTT 
assay. RGD-SAP activity was proportional to an-integrins expression levels, in 
contrast with CYS-SAP, which was around 5-20 folds less active (Fig. 11b). 
Interestingly, as already demonstrated by Curnis et al. [26], we observed an increase 
of cytotoxic activity on anb3+ cells compared to anb6+ cells, meaning that the 
RGD motif is more specific and preferentially binds the mentioned integrin. As for 
ATF-SAP, we used fibroblasts as healthy control in order to evaluate any possible 
off-target effects of the recombinant protein. Strikingly, the effect of RGD-SAP on 
fibroblasts cell viability was significantly lower and negligible compared to cancer 
cells, suggesting that a very low concentration treatment could be very specific 
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Fig. 11 Integrins expression on cancer cell lines and biological activity evaluation of SAP-based 
recombinant proteins. (a) 5637, RT112, RT4, U87, MDA-MB-468- epithelial cancer cell lines and 
fibroblasts were analyzed by flow cytometry for avb3 and avb6 integrins expression. Results are 
shown as histograms (upper left) or RFI (see “Materials and Methods”) (upper right) of a 
representative experiment. (b) The cytotoxic activity was calculated as cell viability after 72 h 
incubation with increasing concentrations of the toxins by MTT assay. CYS-SAP was used as 













Table 4.  SAP-based recombinant proteins in vitro 
activity on cancer cells 
 Toxins cytotoxic activity 
(IC50a) in nM): 
Cell line nb) RGD-SAP CYS-SAP  
U87 3 22,6±6,4 100±54,4 
RT4 3 170±0 750±70,7 
RT112 3 66,6±19,2 500±70,7 
5637 3 120±52 450±14,2 
MDA-MB 468 3 32,5±8,6 187,5±25 
Fibroblasts c) 3 >1000 500 
a) IC50, the half maximal inhibitory concentration (mean±SE); b) 
n, number of independent experiments (each in triplicate); c) 

































































anb3+ anb6- anb3- anb6+ anb3- anb6- 



























































































































































































To determine if the improved delivery of RGD-SAP compared to CYS-SAP relies 
on a targeting mechanism, we explored if it could be partially hampered by a 
competition with the RGD peptide. To this end, cells were treated with RGD-SAP 
or CYS-SAP in the presence or not of a molar excess of RGD. Noteworthy, the 
activity of RGD-SAP significantly decreased in the presence of RGD, in a time 
dependent manner; on the contrary, CYS-SAP activity resulted totally unaffected, 
suggesting that the RGD moiety is well exposed and the presence of SAP does not 
sterically interfere with its binding ability and receptor interaction (Fig. 12a).  
It is well known that SAP toxin induces cell apoptosis. For corroborating evidence, 
we investigated the activation of programmed cell death by analyzing the cleavage 
of caspase 3 in cells treated with RGD-SAP. To this aim, 5637 and MDA-MB-468 
epithelial cells, were incubated with RGD-SAP to perform a time-course analysis. 
DTT, a known apoptosis inducer, was used as a positive control. Cells were lysed 
and analyzed by western blot after 48 and 72 h. As shown in Fig. 12b, sudden and 
massive caspase 3 activation was detectable in all samples treated with the toxin. 
Altogether, these results indicate that fusing the RGD moiety to SAP enhances the 
delivery of the toxin, proportionally to an-integrins upregulation by cells. In 
addition, the cytotoxic activity on cells relies on the uptake and cytosolic release of 
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Fig. 12 RGD-SAP target specificity and apoptosis induction. (a) 5637 bladder cancer cells were 
incubated with RGD-SAP in the presence or absence of a molar excess of RGD peptide. The cell 
viability was evaluated after 48 and 72 h by MTT assay. CYS-SAP was used as untargeted control. 
(b) The activation of the apoptosis pathway upon RGD-SAP treatment was evaluated in 5637 and 
MDA-MB-468 cells by analyzing the intracellular levels of cleaved caspase 3. Cells were incubated 
with RGD-SAP for 48 and 72h and cell lysates were analyzed by western blot with antibodies 
against cleaved caspase 3 and beta-actin for protein normalization. 
 
3.2.7   RGD-SAP has in vivo potent antitumor activity on a subcutaneous 
model of syngeneic bladder cancer  
 
To evaluate the in vivo efficacy of the two SAP-based recombinant proteins 
developed, we firstly established a subcutaneous bladder cancer model C57BL/6 
female wild type mice, by injecting superficial MB49 urothelial mouse carcinoma 
cells in the left flank of the animals. This cell line is sensitive to RGD-SAP, as 
demonstrated in an in vitro assay (Fig. 13a). In the first preliminary experiment, 
five days tumor-bearing mice were treated systemically via tail vein injection with 
a starting 1 mg/Kg dose of RGD-SAP or CYS-SAP toxins and monitored over time 
for the progression of disease. The administration was repeated every five days for 
three times, as shown in the depicted schedule (Fig. 13b).  Despite an initial increase 
of tumor dimensions in all conditions, owing to the high proliferation rate of MB49 
cells, treatment with RGD-SAP was able to delay tumor growth soon after the 
second administration, leading to the complete eradication (n=1) or to a significant 
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caused modest weight loss after the last administration and a severe necrotic effect 
on mice tails (Fig. 13e). CYS-SAP activity on tumor growth was completely null 
and superimposable with PBS-treated mice, meaning that the therapeutic activity 
of RGD-SAP was due to the presence of RGD.  
 
a.                                                                   b. 
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Fig. 13 Effects of RGD-SAP and CYS-SAP on tumor growth in a subcutaneous syngeneic 
bladder cancer mouse model. (a) RGD-SAP in vitro biological activity on MB49 murine bladder 
cancer cell line. (b) Schematic representation of the experimental design in vivo. MB49 cells were 
subcutaneously implanted in 7-week-old C57 WT female mice. Tumor bearing mice were 
randomized into 3 experimental groups and treated respectively with PBS, CYS-SAP (1 mg/Kg) or 
RGD-SAP (1 mg/Kg) via intravenous injection every 5 days after tumor implantation for three times 
(c). Quantitative analysis of growing tumor volume in mice are shown as mean ± SD from n = 4 
mice per condition and as single curves for each individual mouse. Statistical analysis was 
performed by using 1-way ANOVA (*p < 0.05). (d) The mean weight of mice from each treatment 
group is shown as percentage from initial. (e) Pictures of MB49 subcutaneous tumors explanted 
after mice sacrifice are shown. 
MB49






















































































































Next, we wanted to define the in vivo minimum effective dose of RGD-SAP. To 
this end, we used three concentrations of RGD-SAP (0.75, 0.5, 0.25 mg/Kg) and 
maintained the same administration schedule as described above. Although the 
number of injected MB49 cells was reduced, in order to slow down the growing 
speed of the mass, tumor reached measurable dimensions in the same time point (5 
days) in all the animals. Moreover, similarly to the previous preliminary 
experiment, a slight increase of the tumors dimensions was observed in all 
treatment conditions after the first two administration rates. Then, mice treated with 
0.75 and 0.5 mg/Kg RGD-SAP underwent a significant delay of tumor growth 
compared to 0.25 mg/Kg mice, in which a sharp and exponential augment of tumor 
proliferation was detected, similarly to PBS-treated mice (Fig. 14a). In addition, 
0.75 and 0.5 mg/Kg RGD-SAP treatments prolonged animal survival, with no 
evidence of weight loss, thus confirming the RGD-SAP dose dependent activity 
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Fig. 14 Dose dependent effects of RGD-SAP on tumor growth in a subcutaneous syngeneic 
bladder cancer mouse model.  (a) MB49 cells were subcutaneously implanted in 7-week-old C57 
WT female mice. Tumor bearing mice were randomized into 4 experimental groups (n=6) and 
treated respectively with PBS or 3 different doses of RGD-SAP (0.75 mg/Kg, 0.5 mg/Kg or 0.25 
mg/Kg) via intravenous injection every 5 days. Quantitative analysis of growing tumor volume in 
mice are shown as mean ± SD from n = 6 mice per condition and as single curves for each individual 
mouse. Statistical analysis was performed by using 1-way ANOVA (*p < 0.05; **p < 0.01; ***p < 
0.001). (b) The mean weight of mice from each treatment group is shown as percentage from initial. 
(c) Kaplan–Meyer plot of animal survival with median survival time listed in the table. Results from 
a Mantel–Cox two-sided log-rank test are shown (*p < 0.05) for RGD-SAP 0.75 mg/kg (purple; 
hazard ratio, 5.2; 95 % CI, 1.2 – 23.1) versus PBS in mice bearing subcutaneous MB49 tumor. Ns: 
not significant.  
 
Finally, to better understand the effects of the different RGD-SAP doses, we 
collected blood samples at the end of each experiment and analyzed biochemical 
parameters linked to liver and kidney toxicity (albumin, alanine transaminase 
(ALT), aspartate transaminase (AST), creatinine (CHE) and urea). As shown in Fig. 
15 the RGD-SAP systemic toxicity is dose dependent: in fact, significant higher 


























































































































































Fig. 15 Comparison of clinical biochemistry parameters in mice treated with different RGD-
SAP concentrations. Blood samples were collected from retro-orbital plexus and the concentration 
of albumin, alanine transaminase (ALT), aspartate transaminase (AST), creatinine (CHE) and 
urea in the serum were measured. Values are shown as mean ± SD from n ≥ 4 mice per condition. 













































































































































































































































































3.2.8 RGD-SAP pharmacological activity evaluation on an orthotopic mouse 
model of syngeneic bladder cancer  
 
Thereafter, we sought to determine whether the same results were reproducible on 
an orthotopic model of urothelial carcinoma. To this aim, we generated Luciferase 
stably expressing MB49 cells (MB49 luc) and verified the in vitro sensitivity to 
RGD-SAP to be unchanged (data not shown). Thus, luciferase-expressing MB49 
were instilled orthotopically into immunocompetent C57 WT mice and the tumor 
engraftment and progression monitored by in vivo bioluminescence imaging (IVIS) 
(Fig 16). We found successful bladder tumor implantation in all mice within 5-7 
days after cells inoculation.  
a.                                                
  
      b. 
 
        
Fig 16 Orthotopic mouse model of a syngeneic bladder cancer. (a) Luciferase-expressing MB49 
cells were transurethrally injected into the bladder of 7-week-old C57 WT female mice. Tumor 
engraftment was monitored via in vivo bioluminescence imaging (IVIS). Quantitative analysis of 
growing tumor volumes are shown as total photon flux (mean ± SD) from n = 4 mice. (b) Computed 
tomography (CT) images with the corresponding 3D bioluminescence of MB49 bladder tumor 
implanted in mice are shown.   
 
Orthotopic MB49 bladder cancer

































Tumor vascularization was emphasized by bladder ultrasound analysis (Fig. 17).  
 














Fig. 17 Orthotopic MB49 bladder cancer vascularization. Representative ultrasound images of 
mouse bladder before and 15 days after MB49 tumor implantation. Original bladder thickness is 
measured and reported in the image relative to the healthy control (left). Tumor vascularization is 
shown as color Doppler mode (right). 
 
Mice bearing orthotopic bladder cancer were then systemically treated via tail vein 
on days 7, 11 and 16 post-cancer implantation with PBS or RGD-SAP (0.25 and 
0.5 mg/kg) (Fig. 18). No significant differences in both tumor growth and overall 
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Fig. 18 Effects of RGD-SAP on tumor growth in an orthotopic syngeneic bladder cancer mouse 
model. (a) Schematic representation of experimental design. Luciferase-expressing MB49 cells 
were transurethrally injected into the bladder of 7-week-old C57 WT female mice. Tumor 
engraftment and growth was monitored via in vivo bioluminescence imaging (IVIS). Tumor bearing 
mice were randomized into 3 experimental groups and treated respectively with PBS, RGD-SAP 
(0.5 mg/kg) or RGD-SAP (0.25 mg/Kg). (b) Quantitative analysis of growing tumor volume in mice 
are shown as total photon flux (mean ± SD) from n = 10 mice per condition and from each individual 
mouse. (c) The mean weight of mice from each treatment group is shown as percentage from initial. 
(d) Kaplan–Meyer plot of animal survival with median survival time listed in the table. 
 
In order to verify if the lack of response to RGD-SAP is attributable to a high 
growing rate of the cancer cells, which results into a sudden necrosis area formation 
and, as a consequence, into an inadequate drug delivery to the tumor, we decided 


















































































































































































mass. Mitomycin (MMC) is one of the most used agents for the recurrence 
prevention of superficial bladder cancer, usually administered intravesically after 
transurethral resection of cancer lesions. In fact, this administration method, 
together with its moderate hydrophobicity, result in a less systemic absorption and 
limited side effects. We first demonstrated that MB49 bladder cancer cells were 
extremely sensitive to MMC (IC50 ~2 µg/ml) (Fig. 19a), then we used our xenograft 
mouse model to verify if the intravesical administration of MMC might reduce the 
growth speed of the superficial carcinoma mass and necrosis area formation, 
allowing the toxin to reach tumor cells and exert its specific toxic effect (Fig. 19). 
At the time of tumor detection (+7 days after cells infusion into the bladder) all 
cohorts of mice were treated with MMC through transurethral administration. A 
second dose of MMC was given after four days. In between, mice received a first 
systemic regimen of RGD-SAP (0.5 mg/kg) or vehicle (PBS), which was repeated 
for three times as illustrated in the depicted schedule (Fig. 19b). A slowdown of 
cancer progression was not revealed by in vivo imaging after the instillation of 
MMC; however, the combination with RGD-SAP seemed to moderately contain 
the exponential growth and maintain constant the luminescence signal over time 
(Fig. 19c). Even if no statistically significance compared to the other groups, a 
slight synergistic effect of RGD-SAP 0.5 mg/kg combined to MMC could also be 
appreciated on overall survival (Fig. 19e). Furthermore, the treatment resulted to be 
not toxic at all, as mice did not undergo a drop of body weight (Fig. 19d), nor 
evident signs of liver or renal toxicity could be detected by serum analysis of 
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Fig. 19 Effects of MMC and RGD-SAP on tumor growth in an orthotopic syngeneic bladder 
cancer mouse model. (a) Mitomycin C (MMC) in vitro biological activity on MB49 murine bladder 
cancer cell line. (b) Schematic representation of the experimental design. Luciferase-expressing 
MB49 cells were transurethrally injected into the bladder of 7-week-old C57 WT female mice. 
Tumor engraftment was monitored via in vivo bioluminescence imaging (IVIS). Tumor bearing 
mice were randomized into 3 experimental groups and treated respectively with PBS, MMC (50 µg) 
or MMC (50 µg) +RGD-SAP (0.5 mg/Kg). (c) Quantitative analysis of growing tumor volume in 
mice is shown as total photon flux (mean ± SD) from n = 5 mice per condition and from each 
individual mouse. (d) The mean weight of mice from each treatment group is shown as percentage 


























































































































































































Fig 20. Comparison of clinical biochemistry parameters in mice treated with mitomycin C 
(MMC) alone or in combination with RGD-SAP. Blood samples were collected from retroorbital 
plexus and the concentration of albumin, alanine transaminase (ALT) and urea in the serum were 
measured. Values are shown as mean ± SD from n ≥ 4 per condition.  
 
3.3 ATF-SAP and RGD-SAP antitumor activities synergize in a subcutaneous 
model of bladder cancer  
 
Intra-tumor-heterogeneity and the acquisition of resistance to drugs represents the 
main issue to face in cancer treatment. To address this topic, we validated the 
therapeutic potential of a combined toxin based targeted therapy (ATF-SAP and 
RGD-SAP) directed against epithelial derived cancer cells and tumor neo-
vasculature. We demonstrated that stage II muscle invasive bladder cancer cell lines 
RT112 and 5637 maintain a stable uPAR expression, even after serial implantation 
cycles in mice, representing good in vivo models. RT112 in particular, even if less 
uPAR positive compared to 5637, are more sensitive to RGD-SAP in vitro, 
therefore represent an optimal model to appreciate the synergy of the combined 
treatment. In a first preliminary experiment, RT112 cells were injected in the left 
flank of immunocompromised nude mice. After verification of tumor engraftment, 
10 days tumor-bearing mice were intravenously administered with ATF-SAP and 
RGD-SAP as single or combination treatments and monitored for toxic effects. In 
the case of single toxins treatments, we administered a dose equivalent to 0.5 mg/kg 
every 5 days for three times. On the other hand, the same total concentration of 
toxins (0.5 mg/kg, with half doses of each) was given for the combination treatment 
(Fig. 21a). Surprisingly, all groups developed a form of dermatitis after the first 
toxin administration, therefore we decided to reduce the combo dose to 0.25 mg/kg 





































































SAP alone slightly delayed tumor growth and modestly prolonged animal survival 
when compared to untreated mice. Nonetheless, when the two toxins were 
combined, we documented a delated tumor progression similar to controls (ATF-
SAP or RGD-SAP alone) but mice survival was significantly improved (Fig. 21b, 
d). Additionally, no signs of lethargy or weight loss were detected (Fig. 21c). 
Clearly, these results point to synergistic effects of ATF-SAP and RGD-SAP in 
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Fig. 21 Effects of SAP-based recombinant fusions single and combination therapy on tumor 
growth in a subcutaneous xenograft bladder cancer mouse model. (a) Schematic representation 
of the experimental design. RT112 bladder cancer cells were subcutaneously injected in 7-week-old 
nude female mice. Tumor bearing mice were randomized into 4 experimental groups and treated 
respectively with PBS, ATF-SAP (0.5 mg/Kg), RGD-SAP (0.5mg/Kg) or ATF-SAP + RGD-SAP 
(total first dose 0.5 mg/Kg; total following doses 0.25 mg/kg) via intravenous injection every 5 days 
after tumor implantation. (b) Quantitative analysis of growing tumor volume in mice treated with 
single treatments (RGD-SAP or ATF-SAP) (left panel) or combination treatment (RGD-SAP+ATF-
SAP) (right panel) are shown as mean ± SD from respectively n = 6 and n = 5 mice per condition 
and as tumor growth curves for each individual mouse.  (c) The mean weight of mice from each 
treatment group is shown as percentage from initial. (d) Kaplan–Meyer plot of animal survival with 
median survival time listed in the table. Results from a Mantel–Cox two-sided log-rank test are 
shown when statistically significant (**p < 0.01) for RGD-SAP 0.5 mg/kg (blue; hazard ratio, 11.2; 
95 % CI, 1.8 – 69.8) versus PBS, for ATF-SAP 0.5 mg/kg (red; hazard ratio, 19.2; 95% CI, 2.2–
165.8) versus PBS, for ATF-SAP+RGD-SAP (purple; hazard ratio, 19.5; 95% CI, 2.8 – 135.9) 
versus PBS, for RGD-SAP 0.5 mg/kg (blue; hazard ratio, 0.1; 95% CI, 0.1 – 0.5) versus ATF-SAP 
+ RGD-SAP, for ATF-SAP 0.5 mg/kg (red; hazard ratio, 0.08; 95 % CI, 0.1 – 0.5) versus ATF-SAP 































































































































































4.   Discussion I 
 
The production of recombinant proteins has gained great interest in the 
biopharmaceutical sector as an increasing amount of protein drugs are currently 
undergoing preclinical and clinical studies or have been already approved to be on 
the market. Unlike many drugs, proteins are difficult to synthetize in vitro due to 
their complex structure, which is strictly related to their function. Therefore, host 
organisms are usually exploited to produce them throughout biotechnological 
processes. The choice of the most suitable expression host represents a key step in 
the development of this kind of drugs and depends on both the chemical and 
biological properties of the recombinant protein of interest. If complex post-
translational modifications (glycosylation, phosphorylation, etc.) are required to 
ensure an accurate folding, very important to guarantee the protein correct function, 
then a eukaryotic system is usually preferred to bacteria that are not able to provide 
most of the post-translational modifications. Otherwise, in the case of small 
peptides that do not require a complex folding upon synthesis, bacteria represent an 
excellent production system, mostly due to rapid growth, low costs and easy 
management. From a biological point of view, this aspect is even more relevant for 
toxins, considering that they can be lethal for production hosts as well. In the 
present study, we take advantage of ATF-SAP, a recombinant protein in which the 
toxin SAP is fused to the amino-terminal fragment (ATF) of the urokinase 
plasminogen activator, uPA [30, 31, 77]. Due to the length and structure of the ATF 
moiety (a 151 amino acids long peptide, comprising an EGF-like domain or growth 
factor domain-amino acids 12-32- followed by a kringle domain) ATF-SAP 
production was set up in P. Pastoris yeast, in order to both fulfil a proper folding 
and minimize the toxicity for the host organism. In fact, in the present eukaryotic 
organism, the protein can be efficiently segregated into the endoplasmic reticulum 
and subsequently secreted in the culture medium. Thus, ATF-SAP expression has 
been optimized in a fermentation process using lab-scale stirred bioreactor to 
produce discrete batches and demonstrated to be actively cytotoxic on uPAR 
overexpressing U937 leukemia cells [31]. The choice of uPAR as a target arises 
from the clinical evidence of a positive correlation between uPAR expression levels 
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and patient low overall survival in a variety of epithelial and hematological tumors, 
as it is involved in many steps of tumor progression. Hence, it provides the unique 
opportunity to tackle with multiple tumors with a single SAP-based product. As a 
proof-of-concept, a panel of human cell lines resembling bladder and breast cancer 
was analyzed for uPAR expression in order to identify the best model to test ATF-
SAP specificity. We found that high levels of this receptor were mostly confined to 
cells corresponding to the stage II muscle invasive urothelial bladder cancer lines 
and TNBC phenotype, which therefore were selected as suitable in vitro models, 
and proved that ATF-SAP is able to recognize and kill uPAR+ cells, proportionally 
to its expression. As a corollary, cell lines lacking the receptor are not sensitive to 
the chimera, supporting the hypothesis that the presence of ATF enhances an 
efficient tumor targeted delivery of SAP activity. In clinical trials, the 
pharmacological efficiency of current targeted therapies in the treatment of tumors 
usually associates with toxicities deriving from off-tumor expression of the target. 
Besides its implication in cancer evolution, uPAR plays a key role in pericellular 
proteolytic activity, related to tissue remodeling during normal physiological 
condition, such as wound healing and initiation of angiogenesis [14, 16]. Since 
fibroblasts are the most involved cell type in the former cited process, we analyzed 
ATF-SAP activity on a skin fibroblast cell line as well as primary bladder derived 
fibroblasts, in order to predict any potential in vivo side-effect. Even if both types 
of fibroblasts are highly uPAR expressors, ATF does not determine any increase of 
the SAP activity on these cells, failing to exert a cytotoxic effect at the given 
concentrations. Unexpectedly, we also observed ATF-SAP lack of activity on the 
highly uPAR positive MDA-MB 231 TNBC cell line. The reason for such behavior 
could be explained by a differential expression of accessory mechanisms/molecules 
involved in the receptor internalization in highly susceptible tumor cells. To deeper 
understand this phenomenon, we focused on the principal members of the 
plasminogen activation system. It is well known that uPAR endocytosis and 
recycling on the plasma membrane directly relies on different components, among 
which its natural ligand uPA (responsible for the activation of plasminogen 
cascade), the plasminogen activator inhibitor-1 (PAI-1) and the alpha2-
macroglobulin receptor/low-density lipoprotein receptor-related protein (LRP-1). 
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When uPA associates with uPAR, it is converted into the active two-chain form, 
which reacts rapidly with PAI-1, forming a complex that is bound and internalized 
by LRP1. This route leads to the degradation of the ligand and its inhibitor and to 
the turnover of the receptor on the cellular surface, allowing the attenuation of 
proteolytic processes in the extracellular environment [80, 81]. As the activity of 
the chimera was evident in almost all the uPAR expressing cell lines in our hands, 
we wondered if there were some differences in the regulation of LRP1 co-receptor 
or natural ligand uPA compared to fibroblasts and MDA-MB231. Notably, previous 
studies demonstrated that SAP binds to LRP1 in vitro, resulting in its internalization 
in human monocytes and in fibroblasts, further strengthening the importance of this 
receptor in this complex system [51]. In 1997, Fabbrini et al. demonstrated that 
LRP1 is strongly required in ATF-SAP endocytosis. In fact, the observation of toxin 
resistance in LRP1-deficient cells and competition of anti-LRP1 antibodies to ATF-
SAP cytotoxicity, led them to the conclusion that ATF might be necessary for uPAR 
targeting but internalization is due to the binding of the toxin to LRP1 [50, 55]. 
Nevertheless, when we analyzed the LRP1 gene expression and protein localization 
on the plasma membrane, we confirmed its high levels on fibroblasts but not on 
MDA-MB-231 nor on uPAR+ ATF-SAP sensitive cells, suggesting that the SAP-
based chimera internalization does not depend on this co-factor. Similarly, the 
abundant uPA expression in both responding and non-responding cells and the 
absence of a competitive activity with ATF-SAP, excluded the implication of the 
natural ligand in sequestering uPAR, thus reducing its availability on cell surface. 
It is also worth of noting that ATF-SAP only contains the amino terminal binding 
domain of uPA, therefore it is not expected to be able to bind PAI-1 and form the 
complex necessary for the internalization. In fact, no changes in the ATF-SAP toxic 
activity were detected when PAI was added to the medium. On the other hand, when 
we used a SAP conjugate carrying the entire pro-uPA zymogen sequence as 
targeting moiety, the activity of SAP was greatly increased in both fibroblasts and 
MDA-MB-231 cell lines not responding to ATF-SAP. This observation led us to 
suppose that different mechanisms might be involved in the internalization of the 
two SAP-based products. In 2008, Cortese et al. described a novel unusual 
internalization pathway responsible for constitutive endocytosis of uPAR that 
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partially ties with micropinocytosis [82]. They observed that this so far unknown 
endocytosis path does not require the presence of uPA, PAI or LRP1 nor is related 
to uPAR massive expression on cell surface, as it could be detected either on 
naturally uPAR expressing cells and on cells transfected to express exogenous 
uPAR but showing low uPAR levels. Apparently, this micropinocytosis-like 
mechanism is also clathrin- and lipid rafts- independent and associates to a rapid 
recycling of the receptor on the cell surface, therefore it might be important in 
unknown regulations of extracellular functions under particular conditions (i.e. in 
the absence of ligands or inhibitors). Up to now, macropinocytosis is a still poorly 
understood mechanism, constitutively induced in some cell types (e.g. dendritic 
cells and macrophages), but also strictly regulated in cells stimulated with growth 
factors (such as EGF) [82, 83]. In our study we could well distinguish different 
condition which might indicate different internalization pathways: uPAR+ LRP1- 
MDA-MB-468, 5637 and RT112 cells, responsive to ATF-SAP; uPAR+ LRP1- 
MDA-MB-231 cells, not sensitive to ATF-SAP, but turned in a restored SAP 
toxicity when pro-uPA-SAP was used; uPAR+ LRP1+ fibroblasts, not sensitive to 
ATF-SAP but turned in a restored SAP sensitivity when a SAP conjugated to pro-
uPA-SAP. Therefore, we propose a model involving two different internalization 
routes for ATF-SAP chimera or pro-uPA-SAP conjugate: an LRP1 and ligand-
independent endocytosis, induced by the ATF binding to uPAR, mainly detected 
on LRP1 negative cancer cells, but not on MDA-MB231; an LRP1 and ligand-
dependent endocytosis, responsible for the pro-uPA-SAP endocytosis observed in 
LRP1 positive fibroblasts (Fig. 22). The latter could be explained as the need of 
fibroblasts to activate the plasminogen activation system in physiological 
conditions (such as wound healing process) and uptake the proteolytic ligands 
(uPA) in order to attenuate the extracellular process. On the other hand, this 
scenario does not elucidate the lack of cytotoxicity by ATF-SAP in LRP1 negative 
MDA-MB-231 cells that, on the contrary, are sensitive to pro-uPA-SAP. 
Therefore we conclude that ATF-SAP toxic activity does not rely on the presence 
of the uPA:PAI ligands or LRP1 internalization cofactor, but it is likely to stimulate 
a different micropinocytosis-like process that is supposed to faster uPAR turnover 
on the cell membrane. Whether this kind of micropinocytosis is a cell-specific 
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mechanism or if there are cofactors involved in the intracellular sorting machinery 
that might end up in the lysosomal degradation of ATF-SAP are open questions that 
still require further investigation. 
 
a. 






Fig. 22 Schematic representation of internalization pathways proposed for uPAR targeting 
toxins. a. LRP1-uPA-PAI-dependent endocytosis; b. LRP1-uPA-PAI-indipendent endocytosis. 
 
Intra-tumor heterogeneity represents one of the major obstacles for targeting 
therapies, together with the ability of tumor cells to suppress effector response by 
downregulating surface antigens. In order to face this issue, we firstly validated the 
effect of an in vivo environment on the expression of uPAR receptor. RT112 and 
5637 stage II resembling bladder cancer cell lines were used as optimal model for 
this experiment, due to their differential expression of uPAR. We show that after 
serial implantations in mice, both cell lines maintain uPAR levels and 
responsiveness to ATF-SAP, further confirming the suitability of this GPI anchored 
molecule as a target and opening the way to the validation of the chimeric toxin 





































































activity in a preclinical model.  
Next, with the aim to expand the spectrum of targets for SAP-based therapeutics, 
we designed and produced an integrins-targeting recombinant protein, in which 
SAP is fused to RGD targeting peptide. Integrins represent a class of molecules that 
are very important in cell adhesion to the extracellular matrix, with multifaceted 
roles in cancer progression from primary tumor development to metastasis. Their 
attractiveness in the development of anti-cancer drugs mainly resides in their broad 
presence on both epithelial and endothelial cells that is restricted to cancer 
microenvironment. It has already been demonstrated that ACDCRGDCFC-
containing fusion proteins (i.e. RGD-TNF) can be efficiently produced in bacteria 
and provide rapid and stable associations with an-integrins receptors on both 
murine and human angiogenic vessels [26, 27, 28]. In fact, unlike ATF, RGD does 
not need any complex post translational modification other than disulfide bond 
formation. For this reason, we optimized the production process of RGD-SAP in an 
E.coli system. In this case, as bacteria do not have intracellular compartments and 
SAP is toxic for bacterial ribosomes too, we employed an IPTG inducible system 
to limit the dangerous effect of the produced toxin on the host. Therefore, induction 
time, temperature and amount of inducer were strictly defined allowing the highest 
yield of protein production with the lowest toxic effect on the producer.  
Here we show that, even if it is likely that wrong intra-chain disulfide bonds are 
formed between the four cysteines present in the peptide structure, when fused to 
SAP toxin, RGD moiety maintains its ability to recognize and bind an- integrins 
expressing epithelial cancer cells proportionally to their levels, enhancing an in 
vitro significant and selective delivery of the SAP moiety, which causes cell death 
by activating apoptosis program at early time points. Furthermore, competitive 
binding experiments with an excess of RGD free peptide confirmed that its 
improved activity is related to a targeting property other than a passive endocytosis. 
It is worth of noting, however, that we did not measure the anb5 component, for 
this reason we cannot exclude its implication in RGD-SAP activity in all the tested 
cell lines.  
As stated before, our approach is intended to be applied to many cancer subtypes, 
since the target antigens we chose associate with tumor phenotypes with different 
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origins. Here, we focused on testing the pharmacological efficacy of SAP-based 
recombinant proteins in the treatment of bladder cancer. In clinics, bladder cancer 
therapy is characterized by transurethral resection of cancer lesions (TURBT) or by 
the removal of the entire organ (radical cystectomy), depending on the tumor stage. 
Most of the times, a chemoprophylaxis regimen based on chemotherapeutics like 
platinum complexes is given either before surgery (neoadjuvant chemotherapy) or 
after surgery (adjuvant chemotherapy) to lower the chance of cancer recurrence 
[35]. Although the high abundance of molecular antigens [39], targeted therapies 
still do not represent the first choice for the treatment of advanced urothelial 
carcinoma. Here we took advantage of a syngeneic and allogeneic bladder cancer 
mouse models, in order to evaluate: 1- the optimal dosage to achieve a high anti-
tumor efficacy and to limit any possible side effect; 2- the clinical outcome when 
the proposed drugs are used as single or combined therapy. At first, a subcutaneous 
model of MB49 murine bladder cancer, proven to be responsive to RGD-SAP, was 
established on small groups of animals to identify, in a preliminary experiment, the 
minimal effective dose. Interestingly, mice treated with increasing doses of RGD-
SAP (0.5, 0.75 and 1 mg/kg) underwent a significant and dose-dependent reduction 
of tumor growth, while CYS-SAP untargeted control (1 mg/Kg) did not result in 
any anti-tumor effect, as the tumor development in this group of mice was 
superimposable with PBS-treated mice. This observation might indicate that, in 
contrast with CYS-SAP, RGD-SAP is able to reach and actively target the tumor 
environment, excluding a “passive targeting” mechanism caused by the enhanced 
permeability and retention (EPR) effect. However, even if the highest dosage used 
(1 mg/kg) showed an impressive activity, which resulted in tumor debulk in 2 out 
of 5 mice, it was not associated to a significant prolonged mice survival; 
furthermore, the analysis of biochemical parameters revealed liver and renal 
toxicity, evidenced by high aspartate transaminase (AST) and creatinine (CHE) 
plasma levels. No significant differences could be detected between 0.75 mg/kg and 
0.5 mg/kg treatments, which nonetheless had significant effect on tumor growth 
compared to control without side toxicities. Therefore, we decided to use the lowest 
doses 0.5 mg/kg and 0.25 mg/kg to investigate the activity and penetration capacity 
of RGD-SAP in an orthotopic model of bladder cancer. As shown, the intravesical 
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instillation of MB49 cells leads to the formation of a tumor mass which is well 
irrorated through neo-angiogenesis vessels (as shown by ultrasound analysis) and 
superficially proliferates protruding into the bladder lumen. Quite unexpectedly, 
despite these conditions were apparently ideal to examine RGD-SAP therapeutic 
efficiency, no influence on tumor growth in terms of light intensity could be 
appreciated. The reason for this evidence could be attributed to the logarithmic 
proliferation rate of the tumor mass, which results, in few days, in the formation of 
an inner necrotic area that causes hematuria and a sudden drop of luminescence 
signal.  
Mitomycin (MMC) is one of the most used agents considered to be effective in the 
recurrence prevention of superficial bladder cancer [35, 36, 37]. It is usually given 
via trans-urethral instillation for the treatment of stage I superficial bladder 
carcinoma and, due to the administration route and its moderate hydrophobicity, it 
is less absorbed systemically, causing limited side-effects. In this contest, we set up 
an administration schedule in which the intravesical pretreatment of the established 
MB49 bladder tumor with MMC was aimed to slowdown the superficial mass 
growth rate, enabling the formation of new vessels and, thus, an adequate drug 
delivery to the tumor. Interestingly, upon MMC pretreatment, mice receiving 0.5 
mg/kg dose of RGD-SAP incurred in a limited tumor proliferation compared to 
those administered with MMC only or PBS; this outcome also associated with an 
increased overall survival (at the end of the experiment -day 23-, 60 % of mice 
survived upon combined treatment compared to < 40 % in the MMC group and 
only < 20 % in the PBS group) and welfare of mice in terms of body weight and 
systemic toxicity (as observed by the biochemical parameters). Notably, in vitro 
experiments did not report a high cytotoxicity of RGD-SAP on MB49 cells 
(IC50~150 nM); hence, we cannot exclude that the strong in vivo activity of RGD-
SAP is caused by an active integrin targeting of both epithelial and endothelial cells 
in our models. Taken together, these results suggest that RGD peptide is able to 
efficiently deliver SAP to the tumor microenvironment, with potent anti-
proliferative effect. Moreover, the lack of a systemic toxicity associated to liver and 
kidney strongly sustains its specificity, further confirmed by CYS-SAP lack of 
efficiency; in addition, despite RGD-SAP alone apparently did not lower tumor 
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progression in a bladder cancer orthotopic model, probably due to the high 
proliferation rate of MB49 cancer cells, the use of MMC resulted to be a good tool 
to allow RGD-SAP to reach and exert its toxic function on tumor 
microenvironment. 
Since we found the expression of uPAR and an-integrins not to entirely overlap on 
human epithelial cancer cells and since the RGD peptide might be active on murine 
newformed vessels as well, we used a xenograft subcutaneous model in order to 
explore if the combination of ATF-SAP and RGD-SAP could induce stronger 
antitumor effects than single agents. As shown, the combination of the two agents 
induced not only a delay of tumor proliferation and necrotic area formation into the 
tumor mass but also substantially improved mice overall survival when compared 
to single treatments, as the 40 % of mice survived to the end of the experiment (day 
35). Therefore, we conclude that the addition of a targeting moiety to SAP structure 
allows the specific delivery of the toxin to the tumor mass in different models, 
showing promising results in dealing with cancer heterogeneity. Further 
investigations will be addressed to elucidate the exact RGD-SAP cellular targets, 
unravelling the contribution of endothelial cell death in tumor positive response. 
Furthermore, the influence of immune system activation on the reduction of the 
tumor mass remains to be explored as well as the effects of proposed combination 




5.   Results II 
 
5.1 Cells genetic engineering to produce targeting smart prodrug-
encapsulating exosomes 
 
The use of nanotechnology as drug delivery system has gained an increasing 
attention in the last decades. Exosomes, in particular, have been considered 
promising nanovehicles for the intracellular delivery of drugs, including bioactive 
proteins. The presence of a lipid bilayer membrane, in fact, ensures the protection 
of the encapsulated drug from degradation, allowing the achievement of an 
enhanced bioavailability. We herein explore the possibility to use exosomes as 
targeted nanocarriers in order to improve SAP delivery to cancer cells and increase 
its therapeutic outcome. To obtain targeted exosomes, we firstly considered a 
genetic approach, in which we engineered cells to produce targeted cargo-carrying 
extracellular vesicles. To this aim, we fused the RGD peptide encoding sequence 
to the extra-exosomal N-terminus of human Lamp2b cDNA, a typical exosomal 
marker. The cloning strategy adopted was intended at maintaining the Lamp2b 
signal peptide (SP) upstream to the coding sequence, because it is essential for the 
correct Lamp2b sorting into the MVB compartment. In addition, we used an RFP 
reporter gene fused to the C-terminus of the Lamp2b encoding sequence to allow 
its orientation towards the intra-exosomal lumen, enabling vesicles tracking (Fig. 
23). In order to facilitate the release of the cargo protein in the cytosol of the target 
cells, a cleavage sequence GFLG (CS) specific for the cellular protease Cathepsin 
B was then inserted in between the Lamp2b and RFP sequences by PCR 
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Fig. 23 Schematic representation of the modified Lamp2b protein and preparation of the 
fusion product. a. NT, N-terminus; SP, signal peptide; RGD, targeting peptide; CS, cleavage site; 
NACS, non-active cleavage site; CT, C-terminus. b. and c. PCR amplification products of Lamp2b 
(1170bp) and SP (120bp) sequences form HEK293 cDNA and SP-RGD-Lamp2b (1290bp) fusion 
sequence were analyzed by agarose gel electrophoresis.  
 
Cathepsin B is a cysteine protease whose massive expression has been reported in 
several invasive and metastatic cancers [85]. Its presence in cells was monitored by 
western blot analysis and demonstrated to be high, especially in its mature active 
form, in HEK293 and 5637 cells while exosomes derived from both cell lines show 
the presence of Cathepsin B in its native proenzyme non-active form (Fig. 24). 
                                   
Fig. 24 Cathepsin B western blot of HEK293 and 5637 cell lysates and their corresponding 
exosomes. Intracellular and exosomal levels of Cathepsin B were analyzed by western blot with an 
antibody against Cathepsin B, recognizing both the cleaved and the zymogen non-active form. 




























5.2 Lamp2b-fusion product is horizontally transferred to receiving cells  
 
The correct expression of the two RGD-Lamp2b-RFP constructs (CS and NACS) 
by cells was then primarily monitored by fuorescence microscopy. 5637 bladder 
cancer cells were used to this purpose due to their high transfection efficiency (Fig. 
25a). However, even if cells appeared punctuated, confirming the correct 
expression of the protein in the vesicular compartment, we could not detect a high 
fluorescence signal, most of which was confined to the dead cells, suggesting that 
the construct might be cytotoxic for parental cells. To verify the correct sorting of 
the RGD-Lamp2bRFP in the secreted extracellular vesicles and to establish if the 
targeting peptide was correctly localized on the vesicles surface, we transferred 72h 
conditioned medium from 5637 parental cells to receiving HUVEC cells. As 
endothelial cells, in fact, these cells are predicted to express an-integrins on their 
surface and be targeted by RGD peptide [6, 21].  As shown in Fig. 24b, a punctuate 
pattern on HUVEC cells could be distinguished, confirming the transfer via 
extracellular component secreted into the conditioned medium.  
                                        
                        
 
Fig. 25 Lamp2b-RFP recombinant proteins expression and visualization.  a. Representative 
fluorescence microscopy images of 5637 cells 48 h after transient transfection with RGD-Lamp2b-
RFP CS/NACS encoding plasmids. b. Representative images of HUVEC cells 24 h after treatment 
with RGD-Lamp2b-RFP CS/NACS-transfected 5637 conditioned medium. Nuclei were counter 









5.3 Lamp2b fused, RFP-based smart prodrug expression is not stably 
maintained overtime  
 
Having demonstrated that the exogenous gene can be correctly expressed and likely 
conveyed to the extracellular vesicles fraction by parental cells, we sought to 
determine if the expression level and, thus, the extracellular vesicles enrichment of 
the exogenous protein could be increased by the production of stably expressing 
cell clones. Conversely to our expectations, the antibiotic selection resulted in a 
complete loss of both the exogenous proteins, as confirmed by flow cytometry (Fig. 
26). To assess whether the total amount of exogenous protein was relocated to the 
vesicles membrane, western blot analysis was carried out on cell lysates, purified 
microvesicles and exosomes fractions. However, as shown in Fig. 26, no signal 
could be visualized at the molecular weight corresponding to the recombinant 
protein. The same results were obtained when we replaced the RFP sequence with 
SAP encoding gene, indicating that a probable degradation of the exogenous protein 
and adaptation of cells to the antibiotic condition might occur when Lamp2b-fused 
reporters are used. With the aim to exclude a possible cell type specific degradation 
of the RGD-Lamp2b constructs, we performed the same experiments on healthy 
HEK293 cells. As already observed for 5637, neither RGD-Lamp2b-RFP nor RGD-
Lamp2b-SAP expression could be observed after antibiotic selection in the cell 
lysates nor in the purified microvesicles and exosomal fraction. 
                                  




Fig. 26 Exogenous Lamp2bRFP/SAP protein expression in 5637 and HEK cells lysates and 
extracellular vesicles fraction. a. 5637 and HEK293 cells stably expressing the Lamp2b-based 
recombinant proteins (RFP-CS/RFP-NACS) were cultured and conditioned media collected for 
exosomes isolation after 72 hours (left panel). The intracellular, microvesicles (MVs) and exosomal 
content of the exogenous proteins were analyzed by western blot with anti-Lamp2b antibody to 
detect RFP fusion or with anti-SAP antibody to detect the expression of SAP. b. 5637 transfected 
cells were selected with G418 antibiotic for 1 month and analyzed by flow cytometry for 
Lamp2bRFP-CS/NACS expression; results are shown as representative histograms (right panel).  
 
5.4 Tetraspanins-fused, RFP-based smart prodrugs are massively expressed 
by cells and transferred to exosomes 
 
Therefore, we wondered whether the loss of expression of the recombinant products 
was related and confined to Lamp2b marker. To address this question, we cloned 
the RFP CS or NACS sequence downstream to different specific exosomal markers, 
tetraspanins CD9 and CD81. Due to their structure and orientation on the exosomal 
membrane, with both the N- and C-terminus facing the intra vesicle lumen, these 
























































However, as shown in Fig. 27, both 5637 and HEK293 cells efficiently expressed 
the CD9- and CD81-RFP exogenous proteins, in a significant higher extent 
compared to Lamp2b-fused RFP. Interestingly, a different expression pattern could 
be observed between the RFP carrying the active (CS) or non-active (NACS) 
cleavage site, as a more abundant signal was evident in cells transfected with 
CD9/CD81-RFP NACS compared to RFP CS-fused tetraspanins, confirming that 
the active form of Cathepsin B present in both cell types is able to recognize it and 
release the protein from the membrane constriction. This activity could be also well 
distinguished in western blot analysis of 5637 cells lysates, in which the 
quantitative ratio between CD9/CD81-RFP CS and CD9/CD81 alone forms is 
visibly lower compared to CD9/CD81 RFP NACS and CD9/CD81 alone, 
highlighting a high protease specificity against the inserted active cleavage site 
(Fig. 27b). In contrast, we could not observe the same cleavage in healthy HEK293 
cell lysates, in which CD9-RFP CS/NACS were not detectable, while CD81-RFP 
CS/NACS/CD81 alone ratio was comparable. Notably, while HEK 293 cells were 
able to convey the total CD9 exogenous tetraspanin-fused-RFP to exosomes and 
partially the CD81 one, 5637 cells appeared to be completely inefficient in 
transferring the CD9 constructs to exosomes, whereas CD81 exogenous construct 















                          a.                                             b.                              
                             
                      c.                                               d.    
                          
 
Fig. 27 Exogenous tetraspanin-RFP CS/NACS protein expression in HEK293 and 5637 cells 
lysates and exosomal fraction. Fluorescence (left panels) and bright field (right panels) microscopy 
images of HEK293 (a) and 5637 (c) cells stably expressing tetraspanin-RFP (CS/NACS) 
recombinant proteins. Cells were cultured and conditioned media collected for exosomes isolation 
after 72 hours. HEK293 (b) and 5637 (d) cellular and exosomal content of the exogenous proteins 
















































































































































6.   Discussion II  
 
With the aim to improve our toxin delivery system, we isolated and characterized 
nano-sized extracellular vesicles, exosomes, and explored in vitro their potential as 
natural drug carriers. One of the major advantages of using cell derived vesicles 
rather than chemically synthetized liposomes concerns the possibility to completely 
evade the immune system response [93]. In fact, patient-derived healthy cells can 
be isolated and cultured in vitro with the purpose to both genetically engineer them 
to produce therapeutic exosomes or induce them to produce exosomes which can 
be ex vivo manipulated. This approach leads to the prospect to produce personalized 
and well tolerated treatments, as the drug nanocarriers would be recognized as self-
molecules by the patient body, achieving an improved circulation time and 
bioavailability. In this work, we investigated both two different approaches to 
modify exosomes as drug carriers, a genetic and an ex vivo modification of 
exosomes, and considered the advantages of each method in terms of drug 
encapsulation efficiency, delivery capacity and targeting. Regarding the former 
genetic engineering strategy, we used the ACDCRGDCFCG peptide (RGD) 
encoding gene to decorate exosomes surface, in order to better compare the 
exosomes-based targeted delivery system to the recombinant RGD-SAP protein. 
The RGD DNA sequence was cloned at the N-terminus of the Lysosomes-
associated membrane protein 2b (Lamp2b), a membrane protein with a single 
transmembrane domain, already shown to be efficient in displaying targeting 
moieties on the surface of exosomes [65, 71, 72]. This approach has in fact already 
been pursued by Tian et al. in 2013 [71], who produced iRGD-Lamp2b fused 
targeted exosomes and demonstrated their high efficiency in delivering 
chemotherapeutic drugs to breast tumor-bearing in mice. While the above-
mentioned group used electroporation to encapsulate doxorubicin into exosomes, 
in this work we genetically modified the C-terminus of Lamp2b as well, in order to 
couple the tumor targeting property to a selectively releasable drug system in the 
internal lumen of the vesicles. To this aim, we designed a smart-prodrug system, 
taking advantage of a six amino acids sequence (inserted in between the C-terminus 
of Lamp2b and an RFP reporter gene resembling a trackable cargo protein) 
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containing a dipeptide specific for the protease activity of Cathepsin B [84]. 
Cathepsin B is known to be massively expressed in cancer cells but not in healthy 
cells, as involved in many steps of cancer progression [85]. In cancer, Cathepsin B 
is found in lysosomes as well as in vesicles throughout the cytoplasm and at the cell 
periphery [86, 87]. Smart prodrugs systems based on doxorubicin and other small 
molecules, targeting the protease activity of Cathepsin B in tumor 
microenvironment, have already been investigated and demonstrated to be highly 
efficient in kill metastatic cancer cells sparing normal cell [88, 89, 90]. The aim of 
these studies was to selectively release the drugs in tumor microenvironment, 
targeting the secreted Cathepsin B form, which associates to the plasminogen 
cascade and result in the activation of factors involved in the extracellular matrix 
degradation and cancer cells invasion. Herein, the present strategy we proposed is 
directed to avoid the confinement of the cargo protein on exosomes membrane, 
allowing its release in the cytosol of the receiving cancer cells with a high Cathepsin 
B expression. The first step in the development of exosomes-based drug delivery 
systems is the choice of donor cells, which should be able to produce a conspicuous 
amount of extracellular vesicles lacking immunogenic or tumorigenic components. 
As a proof of principles, we selected two different kind of tumor cells as exosomes 
donors, the 5637-bladder cancer cell line and the HEK293 healthy cell line, due to 
their high transfectability and their capacity to produce exosomes without any 
special induction condition. Both cell lines were found to be positive to the active 
cleaved form of Cathepsin B, while exosomes derived from the same cell lines were 
positive for the zymogen non-active form of the enzyme. The expression of the 
Lamp2b recombinant proteins was detectable in its punctuated phenotype on both 
cell types tranfected transiently; furthermore, it could also be well distinguished by 
microscopy observation on endothelial cells receiving donor cells extracellular 
vesicles-containing conditioned medium. However, we found that cells underwent 
a sudden decrease of the signal as soon as they were exposed to an antibiotic clone 
selection. This behavior was further observed by western blot analysis, where the 
presence of the RFP-fused Lamp2b at the predicted molecular weight was not 
detectable neither in the cell nor in the extracellular vesicle fraction (microvesicles 
and exosomes), indicating that there was not a fluorescent signal intensity problem. 
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In addition, a time and selection-dependent loss of expression was also detected 
when the RFP encoding DNA sequence was replaced with the SAP gene, meaning 
that the probable degradation was not cargo-dependent. This phenomenon could 
rely on a cell adaptation to the possible citotoxicity of the constructs, that was not 
related to the presence of the cleavable sequence susceptible to Cathepsin B 
protease activity and, thus, to the selective degradation of the RFP/SAP moiety. In 
fact, the same loss of signal was evident in both cells transfected with the construct 
carrying the active cleavable sequence and its non-active mutant. Consequently, in 
order to verify such a hypothesis, we cloned the RFP gene carrying the CS or NACS 
sequences downstream to different exosomal markers (CD9 and CD81). As shown, 
a high expression of these recombinant proteins could be achieved in both cell 
types, without any downregulation after antibiotics selection. In addition, the 
construct was not only delivered to the extracellular vesicles fraction, but also 
correctly processed by Cathepsin B protease activity, as shown by the differential 
ratio between the fusion products carrying the CS or NACS. Importantly, we could 
distinguish two different intracellular sorting paths of recombinant proteins in the 
cell types we used: while HEK cells were able to direct CD9 fused RFP entirely to 
the extracellular vesicles fraction, in contrast with CD81 fused RFP constructs that 
were detectable both in the cell lysates and in exosomes, 5637 cells were able to 
process both the CD9 and CD81 constructs carrying the Cathepsin B specific 
cleavage site, but not or minimally sort them into the exosomes. Notably, only the 
CD9 fused RFP was correctly processed by 5637 cancer cells, whereas CD81 
resulted in a series of possible degradation products. This result indicate that 5637 
cells represent a good model of cancer recipient cell to test the activity of Cathepsin 
B specific smart prodrugs, showing a highly specific intracellular activity of the 
enzyme; on the other hand, HEK293 cells, represent a good model for production 
of exosomes carrying the Cathepsin B smart prodrug, as the enzymatic activity is 
not detectable at a cellular level and the recombinant proteins are entirely delivered 
to the exosomes fraction. Taken together these results suggest that, conversely to 
what previous studies showed, Lamp2b is not the ideal exosomal marker to produce 
genetically engineered exosomes, as its expression is unclearly downregulated by 
cells under antibiotic selection to make stable expressing cells. In contrast, 
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tetraspanins-based recombinant proteins are able to be massively expressed by cells 
and conveyed to the extracellular vesicles fraction; furthermore, a Cathepsin B 
specific smart prodrug system appeared to be a promising strategy in releasing a 
protein drug specifically to cancer cells when associated to the CD9 tetraspanin. 
However, even if promising, further investigation are needed to verify both an 
effective horizontal transfer of cargo proteins from exosomes to cancer cells and, 
subsequently, to decorate exosomes surface with targeting peptide with a different 




7.   Results III 
 
7.1 HEK293 derived exosomes as suitable and safe potential nanocarriers  
 
Due to the several difficulties we encountered in genetically engineer cells to 
produce therapeutic targeted exosomes, we investigated in parallel the possibility 
of loading SAP into purified exosomes using a different approach based on the use 
of a chemical method. Since exosomes are nanoscale vesicles that reflect the cell 
of origin molecular composition, as already highlighted, it is very important to 
select the proper cell line to produce safe carriers for therapeutic applications. In 
this contest, we opted for the commercially available HEK293 cells as vesicles 
donors, as they have been reported to be one of the systems most frequently used 
to this purpose15. A protocol for the isolation and purification of exosomes from 
HEK293 culture medium, consisting in sequential centrifugation and 
ultracentrifugation steps and in a 0.22 µm filtration to select nano-sized vesicles 
was set up and optimized (Fig. 28a). The collected exosomes were homogeneous, 
with a size distribution picking at 150 nm in diameter as determined by Dynamic 
Light Scattering (DLS) and Nanoparticle tracking analysis (determined by 
Nanosight) (Fig. 28d, e). The presence of typical protein markers (Alix, CD9, CD63 
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Fig. 28 Isolation and characterization of HEK293 derived exosomes. a. Schematic representation 
of exosomes isolation procedure. Exosomes were collected from conditioned medium of 72h 
cultured HEK293 cells by sequential centrifugation and filtration steps. b. Typical exosomal markers 
were detected by western blot analysis with antibodies specific for Alix, CD63, CD9 and CD81. 
Transmission electron microscopy (TEM) (c), Nanoparticles tracking analysis (d) and Dynamic light 









































Labelling procedures represent the easiest way to follow therapeutic nanoparticles 
and to elucidate the interaction with target cells, intracellular trafficking pathways 
and their final fate. To assess whether exosomes can be efficiently captured in vitro 
and trace them once taken up by cells, HEK293-derived purified exosomes were 
labelled with Vybrant DiO, a lipophylic dye able to intercalate into the vesicle’s 
membrane (Fig. 29). Different concentrations of labelled exosomes were firstly co-
incubated with healthy fibroblasts, in order to evaluate the uptake process over time. 
Fluorescent microscopy analysis revealed that the exosomes uptake was time and 
concentration-dependent. Exosomes were visible in the form of green clusters in 
the perinuclear and other subcellular compartments, indicating an efficient 
internalization of the vesicles, that give cells a punctuate aspect. After 72h of 
treatment, the detected increase of cell percentage with a diffused cytosolic signal 
may indicate that exosomal content is likely to be gradually released from the 
endocytic compartment. Moreover, exosomes uptake resulted to be well tolerated 















                     
 
Fig. 29 Exosomes uptake evaluation on heathy and bladder cancer cells a. Healthy skin-derived 
fibroblasts were treated with increasing concentrations (5, 10, 20 µg) of HEK293-derived exosomes 
labelled with the lypophilic dye Vybrant DiO. Exosomes uptake was evaluated over time by 
fluorescence microscopy. b. 5637 and RT112 bladder cancer cells were treated with an intermediate 
concentration (15 µg) of HEK293-derived exosomes labelled with the lypophilic dye Vybrant DiO. 
Exosomes uptake was evaluated after 24h by flow cytometry analysis. Images from a representative 
experiment are shown (n=3).  
 
This result was confirmed by using RT112 and 5637 bladder cancer cells, which 
were co-incubated with labelled HEK-derived exosomes and after 24 hours 
analyzed by flow cytometry. As shown in Fig. 29b, exosomes could enter almost in 
the 100 % of cells, supporting the potential use of these vesicles as drug 
nanocarriers.             
 
7.2 A pH shock exposition enhances SAP incorporation into exosomes 
preserving vesicles structure and uptake property  
                        
So far, different methods have been explored to internalize drugs into extracellular 





with detergents, freeze and thaw cycles. However, even if successful, most of them 
result in a very low drug encapsulation efficiency associated to a strong alteration 
of the exosomal structure [63]. In the present work, we propose a new technique to 
load an exogenous protein, SAP, into isolated exosomes, based on the use of an 
alkaline pH altering buffer, 1 M sodium carbonate pH 11.5 (Na2CO3). The rationale 
of the use of this buffer consists in inducing a membrane reversible perturbation, 
which allows the insertion of the exogenous protein in the vesicle internal lumen. 
To verify this principle, exosomes were exposed to a transient pH shock by 
incubation in the alkaline buffer Na2CO3 and the impact of such pH alteration on 
size and physical structure was analyzed by electron microscopy and Nanoparticle 
tracking analysis. As shown in Fig. 30, we found that Na2CO3 treatment did not 
affect neither exosomes size nor morphology, which appeared to be perfectly 












Fig.  30 Evaluation of structural modifications of exosomes after Na2CO3 treatment. HEK293 
derived exosomes were incubated with alkaline Na2CO3 and then neutralized after 30 min.  The 
impact of the treatment on exosomes size and structure was evaluated through electron microscopy 
(left, scale bar 0.1 µm) and Nanoparticle tracking analysis (right) analysis.   
 
Then, we labelled exosomes with the Vybrant DiO lipophilic fluorescent dye, to 
compare the cellular uptake efficacy of Na2CO3-treated exosomes to PBS-treated 
exosomes as control. As shown, no significant differences could be observed 
between the two conditions, further indicating that a short-term pH shock does not 
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Fig. 31 Chemically treated SAP-encapsulating exosomes uptake. HEK293-derived exosomes 
were incubated with SAP in the presence of PBS (a) or Na2CO3 (b) and stained with Vybrant Dio 
lipophilic dye. After 24h incubation with 5637 cells, exosomes uptake was evaluated by fluorescent 
microscopy (upper panel) and flow cytometry analysis and shown as histogram of one representative 
experiment (lower panel). PBS incubation of exosomes was used as negative control. Different 
concentrations of exosomes (5 and 10 µg) were used for comparison.  
                         
We consequently moved to evaluate the loading capacity of exosomes when 
incubated with Na2CO3. To this aim, exosomes were mixed with SAP in the 
presence of Na2CO3 or PBS as a control. After incubation and pH neutralization, 
the amount of encapsulated SAP was assayed by western blot analysis (Fig. 32). 
The presence of Na2CO3 resulted in a retention of a conspicuous amount of SAP 
compared to PBS-treated samples. Importantly, we wondered if the treatment had 
induced a two-sided transfer of proteins across the exosomal membrane by 
monitoring the presence of Alix, a soluble exosomal protein. As shown in Fig. 32, 
Alix was detectable in exosomes treated with PBS, but not in those incubated with 
PBS




























Na2CO3, indicating that the treatment results in a parallel loss of material by 
vesicles. 
                                                             
Fig. 32 Evaluation of SAP encapsulation efficiency after Na2CO3 treatment. HEK293 derived 
exosomes were incubated with SAP in the presence of Na2CO3 or PBS. SAP encapsulation 
efficiency and exosomes molecular composition alteration were evaluated after Na2CO3 or PBS 
treatment by western blot analysis by sequentially using the antibody specific for SAP and for the 
exosomal marker Alix. Untreated exosomes and seed SAP were used as controls. 
 
As a next step, to confirm that SAP was effectively loaded inside the vesicles and 
exclude any surface aggregation of the toxin, SAP-bearing exosomes were digested 
with a low concentration of proteinase K to degrade the excess of toxin stuck on 
the external membrane, thus preserving exosomal content. An almost complete 
digestion of SAP in exosomes treated with PBS could be achieved as shown by 
western blot analysis, in contrast with Na2CO3 treated exosomes in which SAP was 
still clearly present, even if at lesser extent compared to the untreated control. In 
addition, the detection of Flotillin, a protein associated to the inner leaflet of the 
plasma membrane, confirmed that the protease treatment did not affect the internal 
molecular composition of the vesicles, but its activity was confined to their surface 
(Fig. 33). 
                                    
Fig. 33 Evaluation of effective SAP internalization into exosomes after Na2CO3 or PBS 
treatment. HEK293 derived exosomes were incubated with in the presence of Na2CO3 or PBS. 
After pH neutralization, exosomes were treated with Proteinase K, lysed and analyzed by western 
blot with antibodies specific for SAP, Flotillin and Alix. Untreated exosomes and seed SAP were 


































7.3  Na2CO3 treated-SAP-encapsulating exosomes exert a high cytotoxic 
activity on cancer cells 
 
Hence, we investigated if exosomes loaded with SAP were able to deliver and 
efficiently release their cargo in vitro. To answer this question, stage II bladder 
cancer cells (5637) were treated for 72 h with increasing concentrations (5, 10, 20 
µg) of SAP-bearing exosomes, after Na2CO3 or PBS incubation. Strikingly, 
Na2CO3 treated SAP-bearing exosomes affected cell viability in a dose dependent 
manner and in a significantly more compared to the PBS treatment, demonstrating 
a good protection and intracellular delivery of SAP (Fig. 34).  
           
 
Fig. 34 Chemically treated SAP-loaded exosomes toxic activity. Exosomes were incubated with 
SAP in the presence of Na2CO3 or PBS. 5637 cells were treated for 72 h with increasing 
concentrations (2, 10 or 20 µg) of SAP-bearing exosomes (EXO-SAP) after Na2CO3 (red) or PBS 
(black) treatments. The toxic activity was evaluated by optical microscopy observation (left) and 
MTT assay (right). Exosomes incubated with PBS were used as control. Results are shown as 
mean±SD from three independent experiments. 
 
To achieve a safer SAP protection, limiting the potential toxic effects of the 
unincorporated fraction, we speculated if the addition of a physiological 
concentration of NaCl in the process of SAP encapsulation could reduce the week 
interactions between SAP and exosomal surface. Interestingly, a complete loss of 
SAP retention was observed in PBS treated exosomes by adding salts in the washing 
buffer, in contrast to Na2CO3 treated exosomes in which SAP was still detectable 
(Fig. 35b). Notably, the addition of salts also reduced the amount of SAP associated 





































10 µg SAP-bearing exosomes). However, it is worth of noticing that SAP activity 
appeared to be increased when loaded into exosomes (estimated to be 100 ng 
SAP/µg exosomes, therefore 1 µg SAP are contained in 10 µg exosomes), as a 
conspicuous higher concentration (8 µg) of SAP WT alone was needed to reach an 
IC50 in the same conditions (Fig. 35a). Furthermore, the toxic activity on cancer 
cells was not influenced by the presence of the buffer nor by the presence of the 
excess of non-encapsulated SAP as both of them are completely eliminated during 
the washing procedure with centrifugal filter columns (Fig. 35c, d). 
a.                                          b. 
                                                
 











Fig. 35. Elimination of SAP excess from exosomal surface and evaluation of Na2CO3 
encapsulation efficiency a. 5637 bladder cancer cells were incubated for 72 h with scalar 
concentrations of SAP WT. The effect on cells viability was evaluated by MTT assay and used as 
SAP activity control.  b. Exosomes were incubated with SAP in the presence of Na2CO3 or PBS. 5 
µg of exosomes (EXO or EXO-SAP) or SAP alone exposed to Na2CO3 or PBS treatment were lysed 
and analyzed by western blot analysis for SAP detection after purification by filtration. Increasing 
concentrations of seed SAP were used to as control. c. 5637 bladder cancer cells were treated for 
72h with increasing concentrations (2 and 10 µg) of SAP, SAP-bearing exosomes (EXO-SAP) and 
exosomes alone (EXO) after Na2CO3 (red) or PBS (black) treatments. All samples were filtered with 




























































































































































8.   Discussion III 
 
In order to overcome the limitations related to the genetic engineering of cells to 
produce therapeutic exosomes, we investigated in parallel an ex vitro method to 
customize exosomes as drug delivery nanocarriers. To this purpose, we used non-
cancerous HEK293 cell derived exosomes, isolated from culture medium through 
a specifically refined procedure based on sequential centrifugations and filtration 
and characterized for size and expression of typical exosomal markers. To be an 
ideal drug delivery system, exosomes should not be toxic on recipient cells. Thus, 
as a proof of concept, healthy fibroblasts were firstly analyzed for exosomes uptake. 
We found that these cells were able to capture the vesicles in a concentration and 
time-dependent manner, but no toxic effects could be detected at any time, further 
supporting the safety of the proposed strategy. Moreover, when RT112 and 5637 
bladder cancer cells where co-incubated with labelled exosomes and analyzed by 
flow cytometry, we found that 100% of both cell lines were able to uptake the 
vesicles. Remarkably, the vesicles we used in this study were not subjected to any 
surface modification. In fact, exosomes can either be captured by macropinocytosis 
or deliver their biological content through the receptor mediated endocytic pathway 
[66, 91]. Up to now, many strategies have been developed to load exogenous 
therapeutic cargoes into purified exosomes, including passive incubation with or 
without permeabilization agents (i.e. saponin or detergents), sonication or 
subjection to freeze-thaw cycles [63]. One of the most commonly employed 
exogenous EV loading approach is electroporation, which has been used by many 
research groups to incorporate a wide range of molecules, such as siRNA, small 
molecules, enzymes [63, 64, 65]. Nakase et al. optimized experimental conditions 
to incorporate SAP into extracellular vesicles using this technique [76]. However, 
even if successfully able to introduce exogenous molecules into exosomes lumen, 
all the above-mentioned procedures result in a very low loading efficiency (0.2% 
in the case of SAP [68]) together with a severe structural alteration of exosomal 
morphology. In the present study, we took advantage of a highly alkaline buffer 
Na2CO3, to induce a pH shock perturbing the exosomes membrane and induce SAP 
encapsulation. Na2CO3 was first used in 1982 by Fujiki et al. to isolate 
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intracellular/organellar membranes. They demonstrated that incubation of purified 
fractions of rat liver endoplasmic reticulum (ER), peroxisomes or mitochondria in 
Na2CO3 100 mM induces a conversion of membranes into membrane sheets, able 
to retain only integral membrane proteins but not lipid-anchored proteins [93]. The 
alkaline pH (11.5), in fact, decreases noncovalent protein-­‐‑protein interactions, 
releasing weakly attached peripheral membrane proteins without disrupting the 
integrity of the membranes. In this work, the use of a higher concentration of 
Na2CO3 (1 M) and report the preservation of exosomal structure and exosomal 
uptake efficiency by receiving cells and a good encapsulation efficiency after the 
treatment. The higher concentration of salts used supposedly produced a stronger 
impact on vesicles membrane, creating pores through which an in-and-out 
bidirectional trafficking allows the gain and loss of molecules by the vesicles, as 
shown by the loss of Alix signal. Importantly, we excluded SAP aggregation on the 
surface of vesicles as it was still detectable after protease K treatment, in contrast 
with the PBS treatment, in which SAP was totally lost after digestion. It is worth of 
noticing that proteinase K caused a marked reduction of SAP amount even in 
Na2CO3 treated exosomes. However, a residual amount of the toxin was still 
clearly present and detectable, probably because confined into the vesicle and 
protected by the membrane. Furthermore, the presence of flotillin, an integral 
protein exposed on the internal lumen of vesicles, highlighted the confinement of 
the protease enzymatic activity on the external surface of vesicles, indicating that 
the fraction of SAP still visible was protected by exosomal membrane. The 
difference between Na2CO3 treated SAP-bearing exosomes and the PBS control 
treatment was unambiguously evident in in vitro cytotoxic assay, where the formers 
were able to strongly affect cell viability at very low concentration. Conversely, 
PBS treated SAP-bearing exosomes did not visibly produce any toxic effect even 
at the highest concentration used. Eventually, we demonstrated that the use of a 
physiological concentration of salts (NaCl) in the washing step allows the surface-
attached portion of SAP to be released, lowering the weak protein interactions with 
the vesicle’s membrane. We could, thus, evaluate the method incorporation 
efficiency of SAP to be around 10 %, about 100 times higher compared to the 
commonly used electroporation (0.1 %).  
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However, a direct comparison of the two loading methods should be performed in 
the next future to corroborate the produced data. In conclusion, here we prove that 
a pH shock is a safe and effective method to functionalize exosomes as drug 
carriers, preserving their size and structure and allowing a good loading of a 
therapeutic protein. Nevertheless, to achieve the effective intracellular delivery of 
EV contents, future experiments will be performed in order to customize exosomal 
membrane with chemically conjugated targeting moieties, which must enhance a 
selective and preferential cellular uptake by target cells exploiting a receptor-
mediated endocytosis uptake rather than micropinocytosis (Fig. 36). 
 
 
Fig. 36. Graphical outline of the proposed exosomes-based therapeutic strategy: a starting 
point for future studies. Once isolated from commercially available cultured healthy cells, 
exosomes can be easily manipulated in order to achieve the incorporation of therapeutic molecules, 
by a brief exposure to Na2CO3 pH altering buffer. Therapeutic exosomes specificity will be 
improved by decorating their surface with targeting moieties, which will allow the selective 
recognition and killing of cancer cells in preclinical models of cancer. The future application of the 
proposed method in human cancer treatment will include the use of patient derived healthy cells to 
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